

EMORY UNIVERSITY SCHOOL OF MEDICINE
STANDARD CURRICULUM VITAE FORMAT

1. Name: Ighovwerha (Igho) Ofotokun, MD, MSc
2. Office Address: Emory University School of Medicine
Division of Infectious Diseases
49 Jesse Hill Jr. Drive
Atlanta, GA 30303
Phone 404-616-0659
Fax 404-616-0592
3. E-mail Address: iofotok@emory.edu
4. Citizenship: United States Citizen
5. Current Titles and Affiliations:
 - a. Academic Appointments:
 - i. Primary Appointments:
 1. Professor of Medicine, Division of Infectious Diseases, School of Medicine: 2016 - Present
 - ii. Joint Appointment:
 1. Professor of Behavioral Science and Health Education, Rolling School of Public Health, Emory University: 2016 - Present
 - b. Clinical Appointments:
 1. Staff Physician; Grady Memorial Health System Infectious Disease Program: 2003 – Present
 - c. Other Administrative Appointments:
 1. Program Director: Emory Building Interdisciplinary Research Careers in Women’s Health (BIRCWH): 2015 – Present
 2. Co-Program Director: Atlanta Clinical and Translational Science KL2 Program: 2015– Present
 3. Co-Director, Emory Center for AIDS Research (CFAR), Clinical Core: 2016 – Present
6. Previous Academic and Professional Appointments:
 - i. Medical Officer, Eku Baptist Hospital Nigeria: 1990 – 1994
 - ii. Instructor, School of Medicine, University of Michigan: 1998 – 1999
 - iii. Assistant Professor of Medicine, University of Kentucky: 2001 – 2003
 - iv. Assistant Professor of Medicine, Emory University School of Medicine: 2003 – 2010
 - v. Associate Professor of Medicine, Division of Infectious Diseases, School of Medicine: 2010 - 2016
7. Previous Administrative and/or Clinical Appointments:

- i. Chief Medical Officer, Eku Baptist Hospital, Nigeria: 1993-1994
 - ii. Staff Physician, Ann Arbor Veteran Affairs Medical Center: 1998 – 1999
 - iii. Staff Physician University of Kentucky Medical Center: 2001 – 2003
 - iv. Director, Antimicrobial Stewardship, University of Kentucky Hospital: 2001 – 2003
8. Licensures/Boards:
- i. Michigan Board of Medical Licensure (inactive) Issued: 1995
 - ii. Kentucky Board of Medical Licensure (inactive) Issued: 2001
 - iii. Georgia Board of Medical Licensure (active) Issued: 2003
9. Specialty Boards:
- i. American Board of Internal Medicine Board: 1999, 2009, 2018
 - ii. American Board of Internal Medicine Board (Infectious Diseases): 2002, 2012, 2020
10. Education
- i. B.Sc. Pharmacology, University of Ibadan, Nigeria: 1980 – 1983
 - ii. MB:BS: University of Benin, Nigeria: 1985 – 1990
 - iii. M.Sc: Emory University, Atlanta, GA: 2003 – 2005
11. Postgraduate Training:
- i. Internship in Internal Medicine, University of Michigan, Ann Arbor, Dr. JC Kolars: 1995 – 1996
 - ii. Residency in Internal Medicine, University of Michigan, Ann Arbor, Dr. P. Kazanjian: 1996 – 1998
 - iii. Fellowship, Infectious Diseases, University of Michigan, Ann Arbor, Dr. D. Markovitz: 1999 – 2001
12. Continuing Professional Development Activities:
- i. Emory Medicine Professional Leadership Enrichment and Development Program, EM ProLEAD: 2015
13. Military or Government Service:
- i. Nigerian National Youth Service Corp, 1984-1985
14. Committee Memberships:
- a. National and International:
 - I. NIH-Funded AIDS Clinical Trials Group (ACTG)
 - 1. ACTG Pharmacology Committee, Member: 2002 – 2007
 - 2. ACTG Underrepresented Population Working Group Member, 2004 – 2007
 - 3. ACTG Women’s Health Committee, Member: 2005 – 2007
 - 4. National Institute of Allergy and Infectious Diseases (NIAID)/ ACTG Combination Task Forced on novel antiretroviral combinations for treatment naïve HIV-infected subjects, Member: 2007 – 2011
 - 5. ACTG Translational Research and Drug Development Committee, Member: 2007 – 2009

6. Study Monitoring Committee (Data Safety Monitoring Board – DSMB) for the ACTG, Member: 2007 – 2009
 7. ACTG 5257 study, A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naïve HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir, with Emtricitabine/Tenofovir for Naïve Treatment), Protocol vice-Chair: 2008 – Present
 8. Study Monitoring Committee (DSMB) for ACTG, co-Chair: 2009 - 2012
 9. ACTG 5299 study, A Randomized, Placebo Controlled Phase 1 Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of Subcutaneous Ibalizumab, an anti-CD4 Monoclonal Antibody, in HIV-1 Infected Patients, Protocol Chair: 2010 – 2014
 10. Protocol Member: ACTG 5303 study, A Phase 2b, Double-Blind, Placebo-Matched Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected with R5-Tropic HIV-1, Protocol Member: 2010 – Present
 11. ACTG Bone Working Group, Member: 2012 – Present
 12. ACTG Antiretroviral Therapy Strategies Subcommittee, Member: 2014 – 2016
 13. ACTG-ARTSC broadly neutralizing monoclonal antibodies (bNAbs) Working Group: 2017 – 2018
 14. ACTG Antiretroviral Therapy Strategies Subcommittee, Vice Chair: 2016 – 2017
 15. ACTG Antiretroviral Therapy Strategies Transformative Science Group (TSG), ex-officio chair: 2017 – Present
 16. ACTG Antiretroviral Therapy Strategies TSG Study Monitor Group, Chair: 2018 – Present
- II. NIH-Funded Women Interagency HIV Study (WIHS)
1. WIHS National Executive Committee, Member: 2012 – Present
 2. WIHS Pharmacology Working Group, Member: 2012 – Present
 3. WIHS Metabolic/Cardiovascular Working Group, Member: 2012 – Present
 4. WIHS Female Genital Tract/Pathogenesis Working Group, co-Chair: 2014 – 2016
 5. WIHS Female Genital Tract/Pathogenesis Working Group, Member: 2016 – Present
 6. WIHS/MACS (Multicenter AIDS Cohort Study) Combine Cohort Study Executive Committee, Member: 2017 – Present
 7. MACS/WIHS Investigator Developmental Award Advisory Committee (IDAC) Co-chair, 2018 – Present
- III. Infectious Diseases Society of America (IDSA)/HIV Medicine Association (HIVMA):
1. IDSA Research Committee, Member: 2013 – 2016
 2. HIVMA Research Award Committee, Member: 2013 – 2016
 3. IDSA Publication Committee – IDSA Board Liaison: 2017 – Present

IV. Other National/International Services:

1. Nigerian Medical School Curriculum Review Committee – Reviewed and revised the national curriculum for medical education: 2011 – 2013

- b. Regional:
1. Kentucky HIV/AIDS Advocacy & Action Group, Member: 2001 – 2003
 2. Executive Committee of the Research Education, Training and Career Development (RETC) of the Georgia Clinical and Translational Science Institute (ACTSI), Member: 2009 – Present
 3. Southern Society of Clinical Investigation Nomination Committee, Member: 2016 – Present

c. Institutional:

1. Antimicrobial Subcommittee, University of Kentucky Hospital, Chair: 2001 – 2003
2. Pharmacy & Therapeutic Committee, University of Kentucky Hospital, Member: 2001 – 2003
3. University of Kentucky Hospital Pharmacy Policy and Operations Team, Member: 2002 – 2003
4. Infection Control Committee, University of Kentucky Hospital, Member: 2002 – 2003
5. Emory Infectious Diseases Division Education Committee, Member: 2005 – 2012
6. Emory University Dept. of Medicine Early Career Committee, Member: 2006 – 2010
7. Emory Center For AIDS Research Internal Scientific Advisory Committee, Member: 2006 – Present
8. Grady Health System Pharmacy and Therapeutic Committee, Member: 2007 – Present
9. Emory University Clinical Investigator's Advisory Council, Member: 2008 – Present
10. Executive Committee for Emory University Medical Student Research, Member: 2009 – 2013
11. Department of Medicine Promotion and Tenure Committee, Member: 2011 – 2014
12. Emory Medical Care Foundation Research Committee, Member: 2012 – Present
13. Department of Medicine Career Development Awards (CDA) Committees: I chair 2 of these committees and serve as member on 2 additional ones: 2013 – Present
14. School of Medicine Faculty Committee for Appointment and Promotion: 2014 – 2017
15. Grady Infectious Diseases Program (Grady IDP) Research Steering Committee, Chair, 2015 – Present
16. Executive Committee for the Division of Infectious Diseases, Emory University School of Medicine, Member, 2015 – Present
17. Woodruff Health Sciences (WHSC) Innovative Discovery Subject Matter Expert (SME) Team for the WHSC Strategic Plan, Member: 2017

15. Peer Review Activities:

a. Grants:

i. National and International:

1. Ad hoc Reviewer for NIH (NIAID) Center for AIDS Research Supplemental Grant: 2003
2. Ad hoc Reviewer for Michael Smith Foundation for Health Research: Grant, British Columbia, Canada: 2003 – 2005
3. Ad-hoc Reviewer for the AIDS Clinical Trials Group: 2005 – Present
4. Ad hoc Reviewer NIH Study Section – AIDS Clinical Studies and Epidemiology [ACE]: 2011 – 2014
5. NIH Study Section: Charter Member of the AIDS Clinical Studies and Epidemiology [ACE] Study Section: 2012 – Present
6. NIH Special Emphasis Panels: In addition to serving ACE, I have served on 1-3 special emphasis panels a year (3 already in 2018), including ZRG1 BDA-Q 02 R:PAR10 066 international collaborative project career development, 05 ZAI1 EWS-A (M1) 1P01, and NIAID Clinical Trial Planning Grants review panel. Approximately 12 panels, each reviewing between 2 and 8 grants per session: 2012-Present

ii. Regional:

1. Atlanta Clinical and Translational Science Institute KL2-Mentored Clinical and Translational Research Scholar (MCTRS) Program: 2009 – Present
2. Atlanta Clinical and Translational Science Institute MSCR (TL1) Program: 2009 – Present
3. Study Protocol Reviewer for the Atlanta Clinical and Translational Science Institute (ACTSI) Clinical Interaction Network: 2009 – Present
4. Study Protocol Reviewer for the Atlanta Clinical and Translational Science Institute Scientific Advisory Committee: 2009 – 2015
5. Co-Chair: Atlanta Clinical and Translational Science Institute Scientific Advisory Committee: 2015 – Present
6. Chair, Clinical Interaction Network Scientific Advisory Committee for Georgia Clinical and Translational Alliance: 2017 – Present

iii. Institutional:

- a. Reviewer for Emory Center for AIDS Research – R03 grants: 2008 – Present
- b. Reviewer, Emory Medical Care Foundation Grant: 2012 – 2016
- c. Ad-hoc Reviewer for University Research Committee: 2014 b.

Manuscripts:

1. Antiviral Therapy, 2003 – Present
2. Clinical Infectious Diseases, 2003 – Present
3. Clinical Therapeutics, 2006 – Present
4. Expert Opinion on Pharmacotherapy, 2007
5. Future Medicine: 2008
6. HIV Clinical Trials: 2008 – Present
7. Journal of AIDS Research and Human Retroviruses: 2008 – Present
8. Journal of Clinical Nephrology: 2008
9. Journal of Clinical Microbiology: 2008
10. The Lancet: 2013 – Present
11. Open Forum Infectious Diseases: 2014
12. African Journal of Laboratory Medicine: 2014 – Present
13. Journal of Acquired Immunodeficiency: 2014 – Present
14. American Journal of the Medical Sciences: 2015 – Present

c. Conference Abstracts:

i. National and International:

1. International Conference of African Society of Laboratory Medicine, 2014 – Present.
2. Infectious Diseases Society of America Annual Conference, 2015 – Present
3. Clinical and Translational Science Association Annual Conference, Abstract Judge 2015 – Present

ii.

Institution

al:

1. Emory Medical Student Research Day: Abstract Judge 2012 – Present
2. Department of Medicine Research Day: Abstract Judge 2013 – Present
3. Emory Health Services Research Day: Abstract Judge: 2017 – Present

16. Consultantships/Advisory Boards:

- i. Otsuka Pharmaceutical Development & Communication: 2008 – 2010
- ii. Atlanta Clinical and Translational Science Institute (ACTSI) Scientific Advisory Board,
Member: 2008 – Present
- iii. Resource consultant, Nigerian Government experts' committee on Ebola virus disease and other emerging infectious diseases: 2014
- iv. Food and Drug Administration (FDA): Special Government Employee/Consultant to

FDA Antimicrobial Drugs Advisory Committee: 2015 – 2016

- v. Accordant Health Services: 2016 – Present
- vi. FDA Advisory Committee: Antimicrobial Drugs Advisory Committee, Member: 2016 – Present
- vii. Nigerian Institute of Medical Research (NIMR) Research Advisory Board, Member: 2017 – Present
- viii. Infectious Diseases Society of America Board, Elected Member: 2017 – Present
- ix. HIV Medicine Association Board, Elected Member: 2017 – Present

17. Editorships and Editorial Boards:

- i. Antiviral Therapy, Member, Editorial Board: 2014 – Present
- ii. Journal of the African Society of Laboratory Medicine, Member, Editorial Board: 2015 – Present
- iii. Associate Editor, AIDS Research and Human Retroviruses: 2017 – Present

18. Honors and Awards

- a. Emory Division of Infectious Diseases Shanta M. Zimmer Mentorship Award: 2010
- b. Fellow of the Infectious Diseases Society of America: 2012
- c. HIV Medicine Association (HIVMA) National Research Award: 2013
- d. Emory Department of Medicine Shanthi V. Sitaraman Silver Pear Mentorship Award: 2014
- e. Emory Global Health Institute Fellow: 2014
- f. Emory Department of Medicine Nanette K. Wenger Distinguished Service Faculty Award: 2017
- g. Emory Infectious Diseases Division Paul Beeson's Award: 2018

19. Society Memberships:

- a. Infectious Disease Society of America: 2000 – Present
- b. HIV Medicine Association: 2003 – Present
- c. International AIDS Society (IAS): 2006 – Present
- d. South Society for Clinical Investigation: 2008 – Present
- e. American College of Clinical Pharmacology: 2008 – 2010

20. Organization of Conferences:

- a. National and International:

- i. Administrative Positions:
 - a. Member of the Organizing Committee: The NIH sponsored Annual National Pre-doctoral (TL1) and Post-doctoral (TL2) Programs Meeting: 2012 – Present.
 - b. Annual Scientific Workshop of the Nigerian Institute of Medical Research (NIMR) – Precourse organizer, 2012 – Present
 - c. Member of the Organizing Committee, Infectious Diseases Society of America (IDSA)/NIH Research Fellows Meeting: 2013 – 2018
 - d. IDSA/NIAID Research Fellows Annual Meeting Committee, Vice Chair: 2018 - Present ii.

Sessions as Chair:

- a. Nigerian Institute of Medical Research Annual Scientific Conference, Lagos, Nigeria:
Chair for Grant Writing session, 2012
 - b. Infectious Diseases Society of America (IDSA)/NIH Research Fellows Meeting,
Bethesda, MD: Chair, Mentoring Session: 2013
 - c. Nigerian Institute of Medical Research 2nd International Scientific Conference, Abuja,
Nigeria: Chair for HIV/AIDS session, 2014
 - d. Co-chair, Microbiome seminar organized by NIH/WIHS/MACS, May 13, 2014,
Bethesda, MD
 - e. Co-chair, HIV complications and end-organ damage session at the Infectious Diseases Society of America annual conference “IDWEEK”, October, 2015.
- b. Regional:

- i. Administrative Positions:
 - a. Member of the Organizing Committee of the 3rd Annual Workshop on Antiviral Pharmacometrics, University of Alabama, Birmingham, AL: 2007

21. Community Outreach

- Leadership team – Boy Scout of America, Troop 231: 2012 – 2016
- Children’s Sunday School Teacher – Grace Fellowship Church, Snellville, GA, 2008 – 2011
- Volunteer, Grace Clarkston Clinic (for refugees): 2016 – Present

22. Formal Teaching:

- a. Medical Student Teaching:
 - 1. Infectious Diseases Workshop on antibiotics for M-3 (2 hrs/yr), University of Kentucky: 2001 – 2003
 - 2. M3 Preceptor (1 hr/week) – University of Kentucky Clerkship Program (MD821): 2001 – 2003

3. Precepts M3/M4 during their monthly infectious diseases outpatient clinic rotation through the Grady Infectious Diseases Program (between 4 – 6 students a year in half day/week clinic): 2003 – Present
 4. M2 Preceptor (1 hr/week) – Emory University Clinical Methods: 2003 – 2004
 5. Infectious Diseases Lecture Series (1 hr/yr), Emory University M3: 2003 – 2005
 6. Prologue II (2 hr/yr): Emory University M2 annual workshop on antiretroviral drugs and mechanisms of HIV drug resistance: 2007 – Present
 7. Annual Malaria Lecture: A 1 hr/yr didactic lecture to M2 student: 2009 – Present
 8. Critical Review of the Medical Literature (1 hr/yr): Annual Medical Students' Discovery Phase Lecture: 2010 – 2013
 9. Review of Medical School Discovery Phase Research Proposals (3 hr/yr): 2010 - 2013
 10. Grading of Medical School Discovery Phase Final Research Project Submissions (3 hr/yr): 2010 – 2013
- b. Graduate Programs
- i. Residency Programs:
 - a. Infectious Diseases lecture series: Internal Medicine Noon Conference (1 hr/yr), University of Kentucky: 2001 – 2003
 - b. Precepts medicine house staff during their monthly infectious diseases outpatient clinic rotation through the Grady Infectious Diseases Program (about 3 residents per year in half day/week clinic): 2003 – Present
 - c. Infectious Diseases lecture series (1 hr/yr): Medicine Noon Conference, Emory University: 2008
 - ii. Fellowship Programs:
 - a. Annual case of the week presentation to Infectious Diseases fellows (1 hr/yr): 2003 – Present
 - b. Didactic lectures to infectious Diseases Fellows (1 hr/yr): 2003 – Present
 - c. Co-director – infectious diseases monthly journal club (2 hr): 2008 – 2016
 - iii. Master's and PhD Programs:
 - a. Co-Director: Emory University Masters of Science in Clinical Research (MSCR) monthly Journal Club (1.5 hr/yr): 2009 – Present
 - b. Invited speaker at Emory MSCR Clinical Trial Design, Conduct, and Analysis; BIOS520M on “CONSORT and other publishing guidelines” (1 hr/yr): 2010 – 2013
 - c. Co-Course Director: MSCR592: Emory University MSCR Clinical Research Colloquium Course (2 hr/week – Spring Semester): 2011 – Present c.

Other Categories:

- i. Lecturer, Physician Assistance Infectious Diseases Core lecture (1 hr/yr): University of Kentucky: 2001 – 2003
- ii. Co-Director, Emory Ethiopia Fogarty Scholar and MEPI Scholar Programs Journal Club:

23. Supervisory Teaching:

- a. Postdoctoral Fellows Directly Supervised (served as primary research mentor during infectious diseases fellowship training, master of science in clinical research, and/or M4 Discovery Phase):

Table 1. Previous and Current Mentees				
	Name, Year, Position at start of mentorship	Project and Mentorship Role	Accomplishment	Mentee's Current Position
Current Mentees				
1	Shellee Grim, PharmD 2001 – 2003 University of Kentucky Pharmacy Residency	Clinical HIV/AIDS and Antiretroviral Therapy (Primary clinical mentor)	2 mentored Publications	Clinical Assistant Professor, College of Pharmacy, University of Illinois, Chicago, IL
2	Sarah Smithson, MD, MPH 2005 Emory Medical Student	Liver Enzymes Elevation and Immune Reconstitution among Naïve HIV+ Patients Instituting ART. (Primary research mentor)	1 Mentored Publication ²⁰	Assistant Professor of Medicine, UNC, Chapel Hill, NC
3	Kelly White, PharmD 2006 – 2008 Grady Pharmacy Residency	Evaluation of the Efficacy and Safety of Enfuvirtide Therapy in HIV patients at Grady Health System (Research co-mentor)	1 Mentored Publication ²¹	Senior Clinical Science, Manager, Abbott, Laboratories, Boston, MA
4	Runa Gohkhale, MD 2008 Emory Medicine residency	TDF Associated ARF and Fanconi Syndrome in ART Naïve HIV Patients: Risk Assessment (Primary research mentor)		Epidemic Intelligence Service (EIS) at CDC
5	Julie Gutman, MD, MSc 2008 – 2010 Emory Faculty	Antimalarial PK in <i>P. falciparum</i> infected pregnant women in Brazil (Research co-mentor)	NIH-funded institutional KL2 Award (2008)	Epidemiologist, Malarial Branch, CDC
6	Anandi Sheth, MD, MSc 2008 – 2018 ID fellow 2011 – 2013 Emory Faculty	Pharmacologic modulation of FGT mucosal immunity (Primary research mentor)	4 mentored publications ^{2-4,6,17,19} 2 mentored book chapters IAS young investigator Award (2011) NIH-funded institutional KL2 Award (2012) Emory Medical Care Foundation Award (2012) NIAID K 23 Award (2014-2019) Recipient of R01 equivalent award from the NIH funded Adolescent Trial Network	Associate Professor (09/01/18), Division of infectious Diseases, Emory
7	Lisa Haddad, MD, MPH 2009 – 2018 Family Planning Fellow, 2011 – 2012 Emory Faculty	Safe family planning in high risk population (Primary research mentor)	1 mentored publication ¹⁷ 2 mentored book chapters MPH degree NICHD K 23 award (2014-2019) Recent NICHD R01 recipient	Associate Professor (09/01/17), Dept. of OB-GYN, Emory
8	Emily B. Ambinder, MD, MSc 2010 – 2012 MSCR student Medical student	Antiretroviral induced bone loss (Primary research mentor)	1 mentored Publication ¹⁰ Completed Emory MSCR Recipient of the 2012 CROI Investigator Award Recipient of the 2012 IDSA Medical Scholars Program in the Laboratory Recipient of the 2012 Carolyn L. Kuckein Student Research Fellowship Award	Radiology Residency, Johns Hopkins University
9	Cecile D Lahiri, MD, MSc 2010 - Present	Defining antiretroviral PK/PD in reservoir tissues in women and men (Primary research mentor)	NIH K23 award (2016-2021) Emory KL2 Award EMCF Award NIH supplement 6 mentored peer reviewed publications	Assistant Professor, Division of Infectious Diseases, Emory

10	Kehmia Titanji, PhD 2012 – Present Emory Faculty	B-cell dysregulation and complications of chronic HIV-infection (Primary Research Mentor)	2 mentored publication ² URC Award 2015 NIH K01 Award (2016-2021)	Instructor, Division of Endocrinology, Emory
11	Sandra Zaeh, MD, MPH 2013 Emory Medical Student Discovery Phase	TB screening in HIV-infected individuals in resource limited setting. (Primary research mentor)	1 Mentored Publication ¹⁸ Recipient of the 2012 CROI Investigator Award Recipient of the 2012 IDSA Medical Scholars Program Award Recipient of the 2012 Emory Global Health Institute Individual Field Scholars Award Recipient of the 2012 Benjamin H. Kean Fellowship in Tropical Medicine Award	Internal Medicine Residency, John Hopkins University

Table 1. Previous and Current Mentees

	Name, Year, Position at start of mentorship	Project and Mentorship Role	Accomplishment	Mentee's Current Position
12	Russell Kempker, MD, MSc. 2013 – Present Emory Faculty	Anti-TB PK in cavitary lesions (Research co-mentor)	1 mentored publication ¹⁸ NIAID K 23 (2013-2017) Recent NIAID R21 recipient	Associate Professor (09/01/18), Division of Infectious Diseases, Emory
13	Katherine Dugan, MA, MD 2014 Emory Medical Student Discovery Phase	Effect of lopinavir on human papillomavirus (HPV) infection and cervical cytology among HIV-infected women (Primary Research Mentor)	1 mentored peer-reviewed publication 2 mentored poster abstract presentation 1 mentored oral abstract presentation	OB-GYN Residency, Yale University
14	Alfredo Aguirre, BS, MD 2014 Emory Medical Student Discovery Phase	Do plasma or hair antiretroviral drug concentrations predict persistent lowlevel viremia among HIV-infected women? (Research co-mentor)	1 mentored abstract (submitted)	Internal Medicine Residency – University of California, San Francisco
15	Khadija Jones 2014 – 2015 Emory Undergraduate	Isolation and comparison of Cervical Vaginal Lavage and Peripheral Blood Mononuclear Cells In Women With HIV To Understand The Reliability Of their use in flow cytometry experiments (Primary research mentor)	1 mentored abstract	Emory University Undergraduate – Biology Major
16	Renee Donahue-Carlson, MD 2014 – 2017 ID Fellow	Impact of microbiome changes on antiretroviral (atazanavir, darunavir, and raltegravir) exposure in the FGT (Primary research mentor)	Completed the Emory MSCR program (2016) BMS Virology Fellowship Award (2014) 2 mentored abstract presentations (2016 IAS, 2016 IDWEEK) 2 mentored manuscripts under preparation	Donahue-Carlson, Renee, MD 2014 – 2017 ID Fellow
17	Caitlin Moran, MD, MSc. 2014 – Present Emory Faculty	Predictors of cardiovascular risk in HIV infected women (Primary research mentor)	BMS Virology Fellowship Award (2015) 2 mentored abstract presentation (2017 CROI, 2017 SSCI meeting –oral) Recipient of the CROI Young Investigator Award (2017) Recipient – Emory KL2 Award (2018-2020)	Assistant Professor, Division of Infectious Diseases, Emory
18	Marcos Schechter, MD 2014 – Present ID Fellow	Monitoring responses to Isoniazid Preventive Treatment in HIV-infected individuals (Research co-mentor)		Clinical Fellow, Division of Infectious Diseases, Emory
19	Christina Gavegnano, PhD 2015 – 2017	Defining the viral reservoir and factors driving reservoir persistence and reactivation in HIV-infected women (Research co-mentor)	Successful NIH WIHS supplement - \$70, 000	Assistant Professor, Department of Pediatrics, Emory University
20	Smita Iyer, PhD, 2015 – 2017	Single-cell transcriptional profiling of HIV target CCR5+ α4β7+ CD4 T cells in the female genital tract (Research co-mentor)	Successful NIH WIHS supplement - \$99, 000	Research Instructor, Emory Vaccine Center, Emory University

21	Vasiliki Michopoulos, PhD, MSc 2015 - 2018	The Effects of HIV on Psychophysiological Hyperarousal in Traumatized Women (Research co-mentor)	Successful BIRCHW application – one of 3 inaugural Emory BIRCHW scholars	Research Instructor, Department of Psychiatry and Behavioral Science, Emory University
22	Anar Patel, MD 2016 – 2018 ID Fellow	Impact of microbiome changes on antiretroviral (atazanavir, darunavir, and raltegravir) exposure in the FGT (Primary research mentor)	Accepted into the Emory MSCR program (2016) Recipient, Young Investigator Award, Conference of Retroviruses and Opportunistic Infections (2018)	Private Practice Cincinnati, Ohio
23	Lauren Collins, MD, 2018 - Present	Non-AIDS Co-morbidities in People Living with HIV – The Impact of HIV Serostatus, Age, and Sex (Primary research mentor)	Accepted into the Emory MSCR program (2018)	Clinical Fellow, Division of Infectious Diseases, Emory

b. Residency Program:

1. Consultation Attending Physician, Fellowship Training Program, Infectious Diseases: 2003 – Present
2. Consultation Attending Physician, Medicine Residency Training Program: 2003 – Present

c. Dissertation/Thesis Committees:

1. Member, MSCR thesis committee for Seema P. Kini, MD, MSc: 2009 – 2011
2. Member, MSCR thesis committee for Jennifer A. Whitaker, MD, MSc: 2010 – 2012
3. Member, MSCR thesis committee for Edward A. Stenehjem, MD, MSc: 2010 – 2012
4. Member, PhD dissertation for Amanda M. James, PhD: 2010 – 2013
5. Member, MRSC thesis committee for Ashish Mehta, MD, MSc: 2011 – 2013
6. Member, MSCR thesis committee for Christina Correnti, MD, MSc: 2012 – 2014
7. Member, MSCR thesis committee for Duc Tran, MD: 2013 – 2015
8. Member, MSCR thesis committee for Kobina Wilmot, MD: 2013 – 2015
9. Member, MSCR thesis committee for Seemer Halani, MD: 2016 – 2018

24. Lectureships, Seminar Invitations, and Visiting Professorships:

a. National and International:

1. Antibiotic treatment of intra-abdominal infections: Western Pennsylvania Hospital Internal Medicine Conference, 2001, Pittsburgh, PA
2. Antimicrobial control Effort, University of Kentucky experience: Wayne Ebrite Young Investigators Conference, 2002, West Point, PA
3. Experience in Academic Clinical Research Career in HIV/AIDS: Connecting with Care: Minority HIV Care Providers. 2005, Miami, FL
4. Pharmacology of Antiretroviral Drugs: Mexican HIV/AIDS opinion leaders. 2006, Atlanta, GA
5. HIV Prevention in Rural African Communities Using Small Media Technology. Center for Diseases Control and Prevention (CDC), Global AIDS Project. 2006, Atlanta, GA
6. HIV-management update: CME Program, Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2007, Tampa, FL

7. Impact of Protein Binding on HIV-protease Inhibitors Pharmacokinetics, Antiviral Clinical Pharmacology Laboratory, University of Alabama, 2007, Birmingham, AL
8. HIV Pharmacotherapy update: University of Alabama at Birmingham Antiviral Clinical Pharmacology Lab, 2010, Birmingham, AL. (The audience included participants from UAB, Emory, University of Minnesota, University of Colorado, and University of Nebraska.)
9. Medical School Curriculum: Integration of Basic and Medical Sciences: Presented to the Medical School Review Committee Constituted by the Federal Ministry of Health, 2011, Abuja, Nigeria
10. Pathogenesis of HIV-induced Bone Loss, Infectious Diseases Seminar, Drexel University, 2011, Philadelphia, PA
11. Translational approach towards understanding the long-term complications of HIV infection with emphasis on the skeletal system: Internal Medicine Grand Rounds, (Visiting Professor), University of Michigan Medical Center, 2012, Ann Arbor, MI
12. Mentoring the next generation of clinician scientists. Addis Abba University, Addis Abba, Ethiopia, June 29, 2018
13. Sex differences in the manifestation of infectious diseases, Ethiopia-Emory TB Research Training Program” (EETB-RTP), Debre Zeit, Ethiopia, July, 2018.
14. Recruiting and retaining the hard to reach population in clinical research – lessons learned from the Women’s Interagency HIV Study, National CFAR Adelante webinar, July 10, 2018

b. Regional:

1. Antifungal therapy in HIV/AIDS. Symposium on Antifungal therapy in the New Millennium, 2001, Lexington, Ky
2. HIV/HCV co-infection. Post IDSA/ICAAC symposium, 2002, Lexington, Ky
3. Sex differences in nevirapine clearance. BIRCWH/K-30 retreat, 2002, Lexington, Ky
4. Skin and Soft Tissue Infections, Medical Noon Conference, Medical Center of Columbus, 2004, Columbus, GA
5. Infective Endocarditis; Medicine Grand Round, Medical Center of Columbus, 2004, Columbus, GA
6. Important Drug-drug interaction in HIV management: Medicine noon conference, Medical Center of Columbus, 2006, Columbus, GA
7. Update in HIV Pharmacotherapy: Internal Medicine Grand Rounds, Medical Center of Columbus, 2006, Columbus, GA
8. HIV Management Update: CME Program Atlanta Medical Center, 2006, Atlanta, GA
9. Antiretroviral Resistance: Genotypes & Phenotypes: GA State Ryan White Meeting. 2007, Atlanta, GA
10. HIV/AIDS in 2009; Update and Surgical Issues: Grand Rounds, Morehouse School of Medicine, Department of Surgery, 2009, Atlanta, GA

11. Translation approach towards understanding the impact of HIV-infection in women. Center for Disease Control and Prevention, 2014, Atlanta, GA.
12. Immune dysregulation – a driving force behind HIV associated bone loss. Infectious Diseases Seminar (Visiting Professor). University of North Carolina, 2016 c.

Institutional:

1. West Nile Virus: Neurology Ground Rounds, University of Kentucky, 2002, Lexington, Ky
2. Sex differences in the pharmacological effects of the antiretroviral drugs Emory University Infectious Diseases Seminar, 2003, Atlanta, GA
3. Impact of Sex/Gender on the Effects of Antiretroviral Drugs: Grady IDP Physician Assistant Day Lecture, 2003, Atlanta, GA
4. Assisted Reproductive Technique for HIV-infected Couples; Grady Infectious Diseases Program, 2006, Atlanta, GA
5. Antiretroviral Pharmacokinetics, Grady Infectious Diseases Program Didactics, 2007, Atlanta, GA
6. Emerging Challenges in HIV Pharmacotherapy: Emory Medicine Ground Rounds, 2010, Atlanta, GA
7. Long-Term Complications of HIV-disease Management: The Bone. Emory University Infectious Diseases Seminar, 2010, Atlanta, GA
8. K-award to R01 Conversion: Emory University Pediatric Department, 2011, Atlanta, GA
9. Long-Term Complication of HIV-disease Management: The Bone. Emory University Infectious Diseases Seminar, 2011, Atlanta, GA
10. Translational approach towards understanding the long term complications of HIV infection with emphasis on the skeletal system: Emory Infectious Diseases Seminar, 2012, Atlanta GA
11. Translational approach towards understanding the long term complications of HIV infection with emphasis on the skeletal system: Atlanta VA Medical Center, 2012, Atlanta, GA
12. Updates – HIV and antiretroviral induced bone loss: Atlanta VA Medical Center, 2013, Atlanta, GA
13. Translational approach towards understanding long-term complications of HIV diseases management – Emory Cardiology Research Seminar, 2013, Atlanta, GA
14. Translational approach towards understanding long-term complications of HIV diseases management – Emory Infectious Diseases Research Seminar, 2013, Atlanta, GA
15. Translational approach towards understanding long-term complications of HIV diseases management – Emory Digestive Division Ground Rounds (Internal Visiting Professor), 2014, Atlanta, GA
16. K-club – Transition from K-award to independence in research: Emory University Pediatric Dept. 2014, Atlanta, GA

17. Translational approach towards understanding the long term complications of HIV infection with emphasis on the skeletal system: Atlanta VA Medical Center, 2014, Atlanta, GA
25. Invitations to National/International, Regional, and Institutional Conferences:
 - a. National and International:
 1. Understanding the infective process of the HIV infection. 8th Conference of Association of Nigerian Physicians in the Americas, 2002, Atlanta, GA
 2. Mechanisms of HIV pathogenesis and disease progression in human. 9th Conference of Association of Nigerian Physicians in the Americas, 2003, Chicago, IL
 3. HIV Prevention in Rural African Communities Using Small Media Technology. 11th Conference of Association of Nigerian Physicians in the Americas, 2005, Nashville, TN
 4. Pharmacokinetic Consideration in Antiretroviral therapy: Invited Speaker at Mexico HIV Congress, 2006, Merida, Mexico
 5. HIV-management update: National Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2007, Atlanta, GA
 6. Invited Participant in the NIAID sponsored forum "Opportunity for improving HIV diagnosis, prevention & access to care in the US: 2007, Bethesda, Maryland
 7. Update in HIV-Disease Management: National Conference of the Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2008, Tampa, FL
 8. Update in HIV-Disease Management: National Conference of The Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2010, Tampa, FL
 9. HIV and Bone Disease: Mexico National Infectious Diseases Annual Meeting, 2011, Puebla, Mexico
 10. Translational Approach Towards Understanding the Long Term Complications of HIV Infection. Nigerian Institute of Medical Research Annual Scientific Symposium, 2011, Lagos, Nigeria
 11. Translational Approach Towards Understanding the Long Term Complications of HIV Infection. National Institute of Allergy and Infectious Disease (NIAID)/Infectious Diseases Society of America (IDSA) Infectious Diseases Research Careers Meeting, 2013, Bethesda, MD
 12. Translational Approach Towards Understanding the Long Term Complications of HIV Infection. Nigerian Institute of Medical Research Annual Scientific Symposium, 2013, Lagos, Nigeria
 13. Finding and keeping a mentor. National Institute of Allergy and Infectious Disease (NIAID)/Infectious Diseases Society of America (IDSA) Infectious Diseases Research Careers Meeting, 2013, Bethesda, MD
 14. HIV Reservoir in women – novel Pharmacokinetics / Pharmacodynamics approaches – Women Interagency HIV Study/Multicenter AIDS Cohort Study/ National Institute of Allergy and Infectious Diseases joint annual meeting, 2014, Bethesda, MD
 15. Updates in HIV disease management - National Conference of The Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, 2014, Orlando, FL

16. Ebola virus disease: Nigerian Institute of Medical Research 2nd International Scientific Conference, 2014. Abuja, Nigeria.
17. Chronic HIV infection and end-organ Health – WIHS/NCAB, May 17, 2016, NIH, Bethesda, MD. Symposium session on “HIV Co-morbidities – Preventing and Managing End Organ Disease”. 2016 IDWEEK, New Orleans, LA, October 26-30, 2016

b. Regional:

- i. Individualized HIV Treatment Strategy – State of the Art Lecture: Southern Society for Clinical Investigation Annual Meeting, 2014, New Orleans, LA
26. Abstract Presentations at National/International, Regional, and Institutional Conferences:
 - a. National and International:
 1. Sitwala K*, Faulkner N, Mor-Vaknin N, **Ofotokun I**, Adams B, Markovitz D. Expression and Mechanism of Action of DEK. Poster presented at the International Congress of Immunology. 2001.
 2. **Ofotokun I***, Rapp RP, Empey KL, Martin C, Evans ME, Armistead JA. Result of a four year effort to control the use of antimicrobial agents at a University-affiliated hospital. 40th IDSA meeting, Chicago Oct 22-27, 2002. Poster Abstract 601.
 3. **Ofotokun I***, Pomeroy C, McNamara P. Sex difference in nevirapine clearance. 41st IDSA meeting, San Diego Oct 9-12, 2003. Poster Abstract 87.
 4. O'Neil KL*, **Ofotokun I**, Googe H, Patel M. Evaluation of the efficacy and safety of enfuvirtide therapy in HIV patients at Grady Health System, 39th ASHP Midyear Clinical Meeting, Orlando Florida Dec 5-9, 2004. Poster Abstract PR 76
 5. **Ofotokun I***, Smithson S, Lu C, Easley KA, Lennox JL. Association between Hepatitis B and C Sero-status Antiretroviral Related Liver Enzymes Elevation and Immune Reconstitution Among Treatment Naïve HIV-Infected Patients. Presented at the 43rd annual meeting of the Infectious Diseases Society of America. Oct. 6-9, 2005 San Francisco. Poster Abstract #876
 6. **Ofotokun I***, Binongo J.N.G., Favaloro-Sabatier J., Easley K.A., Lennox J.L., Kane M. Knowledge, Attitudes, Beliefs and Practices of Residents of Three Rural African Communities. XVI International AIDS Conference, Toronto 13-18 August, 2006: Poster Abstract: A-011-0160-11562.
 7. **Ofotokun I***, Kane M, Binongo J, Binongo J.N.G., Favaloro-Sabatier J. HIV/AIDS Education Program Using Small Media-based Technology for Oral Communicators at the Community Level to Enhance HIV/AIDS Awareness. The 2006 HIV/AIDS Implementers' Meeting in Durban, South Africa, June 12-15, 2006: Abstract #C9/124. Oral Presentation.
 8. **Ofotokun I***, Chuck SK, Palau M, Binongo, Acosta JE, Lennox JL. Lack of Sex Differences in Once Daily Lopinavir/ritonavir (LPV/r) Pharmacokinetic (PK) Profile. Program and Abstracts of the Eighth International Congress on Drug Therapy in HIV Infection. 12-16 November 2006. Glasgow, UK. Poster Abstract #296.
 9. **Ofotokun I***, Acosta E, Lennox J. Pharmacokinetics of an indinavir/ritonavir/fos-amprenavir regimen in HIV-infected individuals. Poster presentation at the 4th IAS Conference, Sydney, Australia, July 22-25, 2007.

10. **Ofotokun I***, Chuck S, Rivas M, Rode R. Switching from lopinavir/ritonavir (LPV/r) soft gel capsule (SGC) to Tablet formulation improves tolerability. Poster Abstract and Program of the 45th annual meeting of the Infectious Diseases Society of America, Oct 4 – 7, 2007, San Diego.
11. King JR*, **Ofotokun I**, Rivas M, Johnson VA, Acosta EP. Integrating Pharmacokinetics and Antiretroviral Resistance Testing in Clinical HIV-1 Management. Poster Abstract, 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb. 3 – 6, 2008.
12. **Ofotokun I***, Lennox L, Eaton M, Ritchie J, Acosta E. Immune Activation Mediated Change in the Plasma Binding Protein Alpha-1-Acid Glycoprotein Alters Plasma Lopinavir Concentrations. Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010 at Moscone Center West in San Francisco, CA. Poster Abstract #N-105.
13. **Ofotokun I***, Lennox L, Long M, Ritchie J, Acosta E. Circulating levels of alpha-1-acid glycoprotein do not affect free lopinavir pharmacokinetic profile. Program and Abstracts of the 11th International Workshop on Clinical Pharmacology of HIV Therapy; 7 – 9 April, 2010, Sorrento, Italy. Poster Abstract #44.
14. **Ofotokun I***, Weitzmann NM, Vunnavva A, Sheth A, Villinger F, Zhou J, Williams EB, Sanford SE, Rivas M, and Lennox JL. HAART-Induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS. Oral Presentation in the Program and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011 at Hynes Convention Center in Boston, MA. Abstract #O-102.
15. Acosta EP*, Limoli KL, Trinh L, Parkin NT, King JR, Weidler J, **Ofotokun I**, and Petropoulos CJ. Novel method to assess antiretroviral target trough concentrations using *in vitro* susceptibility data. Poster Abstracts, the 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011 at Hynes Convention Center in Boston, MA. Abstract #N-145.
16. Sheth AN*, Evans-Strickfaden T, Martin A, Gatcliffe C, Adesoye A, Omondi M, Haaland R, Lupo LD, Easley KA, Pau CP, Hart C, **Ofotokun I**. Genital secretions of HIV-1 infected women on effective antiretroviral therapy contain high drug concentrations and low amounts of cell-free virus. Oral Presentation of the Program and Abstracts of the 6th International AIDS Society Conference, July 17 – 23, 2011. Abstract #290.
17. **Ofotokun I***, Sheth AN, Easley KA, Shenvi N, White K, Eaton M, Del Rio C, Lennox JL. Switching Antiretroviral Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-infected Patients is Safe and Well Tolerated (The KITE Study). Poster Abstract, 6th International AIDS Society Conference, July 17 – 23, 2011. Abstract # CDB272.
18. McIntosh E*, Vunnavva A, Lennox JL, Weitzmann MN, and **Ofotokun I**. Suppression of formation threatens delayed-phase bone loss in virologically HIV+ individuals on chronic ART. Program and Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections, March 3-5, 2012, Seattle, WA. Poster Abstract #877.
19. James A*, King K, **Ofotokun I**, Sheth A, and Acosta E. Determination of Tenofovir (TFV) and Emtricitabine (FTC) Uptake *in vitro* with Non-Monocytic Genital Tract Cells. Program and Abstracts of the 19th Conference on Retroviruses and Opportunistic Infections, March 3-5, 2012, Seattle, WA. Poster Abstract #586.

20. Sheth AN, **Ofotokun I***, Buchacz K, Armon C, Baker R, Brooks J, , Palella F. Antiretroviral regimen durability in treatment-naïve and treatment-experienced patients by year of treatment initiation, United States, 1996–2008. Poster Abstract, XIX International AIDS Conference (AIDS 2012), to be held in Washington, D.C., 22-27 July 2012.
21. Titanji K*, Vunnava A, Sheth A, Lennox J, Weitzmann MN, **Ofotokun I**. B Cell Dysregulation Promotes HIV-induced Bone Loss. 20th Conference of Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Poster Abstract.
22. Landovitz RJ*, Tran TTT, Cohn SE, **Ofotokun I**, Lennox JL, Currier JS, Ribaldo HJ. HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. 20th Conference of Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Poster Abstract.
23. Zaeh S*, Kempker R, Stenehjem E, Blumberg HM, **Ofotokun I**, Tenna A. Improving Tuberculosis Screening and Isoniazid Preventative Therapy in an HIV Clinic in Addis Ababa, Ethiopia. 20th Conference of Retroviruses and Opportunistic Infections, Atlanta, GA, 2013. Poster Abstract.
24. Delille CA*, Pruett ST, Marconi VC, Armstrong WS, Lennox JL, Arrendale RF, Sheth AN, Easley KA, and **Ofotokun I**. Degree of Plasma Protein Binding Affects Central Nervous System (CNS) Penetration of the HIV-1 Protease Inhibitors. Oral Abstract, *2nd Annual NIAID/IDSA Research Careers Meeting*. June 6-8, 2013. Bethesda, Maryland.
25. Wang K*, D'Argenio D, Sheth A, Lennox JL, Acosta EP, and **Ofotokun I**. Integrated Model of Lopinavir Pharmacokinetics and HIV-1 Viral Dynamics: The Role of α -1-acid Glycoprotein Binding. 2013 ACoP, Poster Abstract, Fort Lauderdale, FL.
26. Wang K*, D'Argenio DZ, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-wood C, and **Ofotokun I**. Integrated population pharmacokinetic and viral dynamic modeling of lopinavir/ritonavir in HIV-1 treatment naïve patients. 4th International Symposium in Quantitative Pharmacology, Beijing, China, November 1-3, 2013 (Janssen Poster Excellence Award, First Prize).
27. Landovitz RJ*, Ribaldo HJ, **Ofotokun I**, Wang H, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, and Lennox JL and the A5257 Study Team. Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC/tenofovir. 21st Conference of Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston. Oral abstract 85.
28. **Ofotokun I***, Ribaldo H, Na L, McComsey G, Cohn S, Godfrey C, Sagar M, Aweeka F, Lennox J, Currier J. Darunavir or atazanavir versus raltegravir lipid changes are unlinked to ritonavir exposure: ACTG 5257. 21st Conference of Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston. Poster abstract 746.
29. Larson KB, Wang K, James AM, **Otofokun I***, Sheth A, Delille C, Vunnava A, Acosta EP. Population analysis of tenofovir plasma and intracellular pharmacokinetics in female HIV-1 seropositive patients. 15th Antiretroviral PK Workshop, Washington DC, 2014. Oral abstract.
30. Delille CA*, Burk RD, Palefsky JM, Massad LS, Reimers L, Minkoff H, Xie X, D'Souza G, Xue X, Colie C, Anastos K, Dugan KB, Wingood G, Strickler HD, **Ofotokun I**. Lopinavir Use and Human Papillomavirus (HPV) Infection in HIV Positive Women. (Poster). *29th International Papillomavirus Conference*. August 21-25, 2014. Seattle, Washington.

31. Aguirre AJ, Mehta C, **Ofotokun I***, Gandhi M, Hussen SA, Merenstein D, Kashuba AD, Anastos K, Kempf MC, Golub ET, Greenblatt RM, Dehovitz JA, Milam J¹, Cohen MH¹, Sheth The prevalence of persistent low-level viremia and virologic failure among a cohort of HIV-infected women on antiretroviral therapy. Poster Abstract, CFAR Symposium on HIV Research in Women. December 8-9, 2014. Buffalo, NY.
32. Natanzon Y*, Zhu X, Morris N Sharma A, Gustafson D, Liu CL, Greenblatt R, Pearce L, Adeyemi O, Irvin R, Dykxhoorn D, **Ofotokun I**, Floris-Moore M, Pierce C. Preliminary Candidate Gene Analysis In The Women'S Interagency HIV Study Shows Pleiotropic Effect Of APOB4 And Novel Associations Of BMP4 And NOS3 With Metabolic Syndrome Traits. HYPERTENSION Volume: 64 Supplement: 1 Meeting Abstract: 274 Published: SEP 2014
33. Vardhanabhuti S*, Ribaldo H, Raphael Landovitz R, **Ofotokun I**, Lennox J, Currier J, Olson L, Haas D. *UGT1A1* Genotype Predicts Bilirubin-related Discontinuation of Atazanavir/Ritonavir. 22nd Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2015
34. Swaims A*; Evans-Strickfaden T; Lupo LD; Aguirre A; Sheth S; **Ofotokun I**; Hart C; Haaland R. Progesterone Increases are Associated With HIV Susceptibility Factors in Women. 22nd Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2015
35. Sarkar M*, Dodge JL, Greenblatt Ruth, Kuniholm MH, Dehovitz J, Plankey M, Kovacs A, French A, Seaberg EC, **Ofotokun I**, Fischl M, Overton ET, Kelly E, Bacchetti P, Peters MG.
Reproductive Aging, Independent of Chronologic Age, Is Associated with Accelerated Fibrosis Progression in HIV/HCV Co-Infected Women. Conference: 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) Location: San Francisco, CA Date: NOV 13-17, 2015, Sponsor(s): Amer Assoc Study Liver Dis. HEPATOLOGY Volume: 62 Special Issue: SI Supplement: 1 Pages: 914A-915A Meeting Abstract: 1444 Published: OCT 2015
36. **Ofotokun I***, Titanji K, Vunnava V, Foster A, Sheth AN, Lahiri CD, Lennox JL, Knezevic A, Easley KA, Weitzmann MN. A Single Dose Zoledronic Acid Prevents Antiretroviral-Induced Bone Loss. Oral presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
37. Ribaldo HJ*, Landovitz RJ, Na LH, Lennox JL, **Ofotokun I**, Cohn SE, Kuritzkes D, Currier JS for the ACTG A5257 Study Team. Gender and Racial Disparities in Initial Antiretroviral Treatment Outcome: ACTG A5257. Poster presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
38. Landovitz JL*, Tran TT, Cohn SE, **Ofotokun I**, Bishopric GA, Lennox JL, Currier JS, Ribaldo JJ. Perception of Infectiousness in HIV-Infected Persons After Initiating ART: ACTG A5257. Oral presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
39. Chan ES*, Mirmonsef P, Brown TT, Landay AL, **Ofotokun I**, Weitzmann MN, Martinson J, Plants J, Ribaldo HJ, Taiwo B. Immunologic Effects of Maraviroc vs Tenofovir and Associations With Bone Loss. Poster presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.

40. Sheth AN*, Iyer, SS, Sabula MJ, Brown NL, Haddad LB, Mehta CB, Amara RR, **Ofotokun I**. The Effect of Sampling Strategy on Phenotypic Characteristics of HIV Target Cells in the Female Genital Tract. Conference: Conference on HIV Research for Prevention (HIV R4P) Location: Chicago, IL Date: OCT 17-20, 2016. AIDS RESEARCH AND HUMAN RETROVIRUSES Volume: 32 Supplement: 1 Pages: 306-306 Meeting Abstract: P18.03 Published: OCT 2016
41. Bhagwat P*, **Ofotokun I**, McComsey GA, Brown TT, Moser CB, Ribaud HJ, Sugar CA, Currier JS. Measurement of Abdominal Fat Changes in HIV-Infected Individuals Initiating Therapy. Poster presentation at the Conference of Retroviruses and Opportunistic Infections, Boston, MA, 2016.
42. Donahue Carlson R*, Sheth AN, Read T, Frisch M, Mehta C, Martin A, Evans-Strickfaden T, Haaland RE, Pau C, Kraft C, Hart CE, **Ofotokun I**. The female genital tract microbiome is associated with vaginal antiretroviral drug concentrations in HIV-infected women on antiretroviral therapy. Poster Presentation at the 21st International AIDS Conference, Durban, South Africa, July 18-22, 2016, # A-792-0175-02699
43. Haddad LB*, Wall K, C. Christina Mehta CC, Elizabeth Golub E, Rahangdale L, Kempf M, Karim R, Wright R, Minkoff H, Cohen M, Kassaye S, Cohan D, **Ofotokun I**, Cohn SE. Trends and predictors of pregnancy and abortion rates among HIV infected and uninfected women enrolled in Women's Interagency HIV study (WIHS): 1994-2012. Poster Presentation at the 21st International AIDS Conference, Durban, South Africa, July 18-22, 2016, # A-792-0342-07247
44. Titanji K, Vunnava A, Sheth AN, Lahiri CD, Lennox JL, Foster A, Weitzmann MN, **Ofotokun I***. Contribution of T cells to RANKL/OPG imbalance and bone loss in HIV infection. Poster Presentation at the 21st International AIDS Conference, Durban, South Africa, July 18-22, 2016, # A-792-0127-08875
45. Moran CA*, Vunnava A, Sheth AN, Mehta C, Tien P, Plankey M, Golub ET, Quyyumi A, Kaplan RC, **Ofotokun I**. CRP predicts subclinical CVD progression in HIV- but not HIV+ women. Abstract #629, poster presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
46. **Ofotokun I***, Titanji K, Vunnava A, Foster A, Sheth AN, Lahiri CD, Lennox JL, Knezevic A, Easley KA, M. Weitzmann MN. Antiretroviral bone loss is durably suppressed by a dose of zoledronic acid. Abstract #684, poster presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
47. Bhagwat P*, **Ofotokun I**, McComsey GA, Brown T, Moser C, Sugar CA, Currier JS. Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation. Abstract #695, oral presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
48. Weiser S*, Sheira LA, Palar K, Wilson T, Metsch L, Adimora A, **Ofotokun I**, Wentz E, Tien P, Frongillo EA. Food insecurity and HIV treatment outcomes in the Women's Interagency HIV Study. Abstract #913, poster presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.
49. Haddad LB*, Kohlmeier AS, Haaland R, Brown N, Lupo D, Mehta C, Sheth AN, Titanji K, Hart C, **Ofotokun I**. Changes in genital-tract HIV target cells with three progestin-based

contraceptives. Abstract #943, oral presentation at the Conference of Retroviruses and Opportunistic Infections, Seattle, WA, 2017.

50. Lahiri CD*, Brown N, Chien H, Vunnavu A, Ryan K, Acosta EP, Sheth AN, Ingersoll J, **Ofotokun I**. HIV RNA persists in rectal tissue despite virological suppression in blood plasma with dolutegravir-based combination antiretroviral therapy in treatment-naïve patients. Abstract, oral presentation at International AIDS Conference, Paris, France, 2017. b. Regional:

1. McIntosh E*, Vunnavu A, Lennox JL, Weitzmann MN, and **Ofotokun I**. Suppression of formation threatens delayed-phase bone loss in virologically HIV+ individuals on chronic ART. Oral presentation. 2012 Southern Regional Meetings, New Orleans, LA.
2. Zaeh S*, Kempker R, Stenehjem E, Blumberg HM, **Ofotokun I**, Tenna A. Improving Tuberculosis Screening and Isoniazid Preventative Therapy in an HIV Clinic in Addis Ababa, Ethiopia. Oral presentation. 2013 Southern Regional Meetings, New Orleans, LA.
3. Delille CA*, Burk RD, Palefsky JM, Massad LS, Reimers L, Minkoff H, Xie X, D'Souza G, Xue X, Colie C, Anastos K, Dugan KB*, Wingood G, Strickler HD, **Ofotokun I**. Lopinavir Use and Human Papillomavirus (HPV) Infection in HIV Positive Women. Poster presentation. 2015 Southern Regional Meetings, February 26-28, New Orleans, LA. c. Institutional:

1. **Ofotokun I***, Lennox L, Long M, Ritchie J, Acosta E. Circulating levels of alpha-1-acid glycoprotein do not affect free lopinavir pharmacokinetic profile. Poster presentation. 2010 Department of Medicine Research Day, Emory University, Atlanta, GA.
2. **Ofotokun I***, Weitzmann NM, Vunnavu A, Sheth A, Villinger F, Zhou J, Williams EB, Sanford SE, Rivas M, and Lennox JL. HAART-Induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS. Poster presentation. 2011 Department of Medicine Research Day, Emory University, Atlanta, GA.
3. McIntosh E*, Vunnavu A, Lennox JL, Weitzmann MN, and **Ofotokun I**. Suppression of formation threatens delayed-phase bone loss in virologically HIV+ individuals on chronic ART. Poster presentation. 2012 Medical Students Research Day, Emory University, Atlanta, GA.
4. Zaeh S*, Kempker R, Stenehjem E, Blumberg HM, **Ofotokun I**, Tenna A. Improving Tuberculosis Screening and Isoniazid Preventative Therapy in an HIV Clinic in Addis Ababa, Ethiopia. Oral presentation. 2013 Medical Students Research Day, Emory University, Atlanta, GA.
5. Delille CA*, Pruett ST, Marconi VC, Armstrong WS, Lennox JL, Arrendale RF, Sheth AN, Easley KA, and **Ofotokun I**. Degree of Plasma Protein Binding Affects Central Nervous System (CNS) Penetration of the HIV-1 Protease Inhibitors. Poster presentation. 2013 Department of Medicine Research Day, Emory University, Atlanta, GA.
6. Delille CA, Dugan KB*, Burk RD, Palefsky JM, Massad LS, Reimers L, Minkoff H, Xie X, D'Souza G, Xue X, Colie C, Anastos K, Wingood G, Strickler HD, **Ofotokun I**. Lopinavir Use and Human Papillomavirus (HPV) Infection in HIV Positive Women. Poster presentation. 2014 Department of Medicine Research Day, Emory University, Atlanta, GA.

27. Research Focus:

My research is focused on clinical/translational work in women's health in the setting of HIV/AIDS with emphasis on antiretroviral clinical pharmacology and long-term (bone) complications of HIV disease management. I am also committed to mentoring and career development for the next generation of translational investigators in women's HIV/AIDS research.

28. Grant Support:

a. Active Support:

i. Federally Funded

- | | | | |
|--|--|----------------------------|---------------------|
| 1. | NIH U54 (Ofotokun/Haddad AG062334)
NIA | 2018 – 2023
\$1,515,946 | 2.4 calendar month |
| <p><u>Emory Specialized Center of Research Excellence (SCORE) on Sex Differences</u>: This application will explore the pathways underlying the influence of biological sex in the manifestations of infectious diseases using HIV as a model, with the hope of shedding additional light on the pathology and the pathogenesis underlying sex-mediated responses to chronic infections in order to enhance the development of interventions that take these factors into account.</p> | | | |
| <p>Role: Principal Investigator</p> | | | |
| 2. | NIH-U01 (Ofotokun AI103408)
NIAID | 2013 – 2018
\$2,519,163 | 2.4 calendar months |
| <p><u>Emory WIHS CRS - Longitudinal Cohort</u>: The purpose of this proposal is to recruit and retain a diverse cohort of eligible women representative of the local epidemic in the state of Georgia into the Women Interagency HIV Study cohort. Role: Principal Investigator (PI)</p> | | | |
| 3. | NIH-R38 (Ofotokun/Roupheal AI140299)
NIAID | 2018 – 2022
\$344,760 | .12 calendar months |
| <p><u>Emory R38 StARR Program</u>: The goal of this program is to leverage the rich infrastructure and the interdisciplinary research environment at Emory to provide clinical and translational research training for resident physicians in the field of infectious diseases, microbiology, and immunology.</p> | | | |
| <p>Role: Contact PI/co-Program Director</p> | | | |
| 4. | NIH-U01 (Lennox AI069418)
NIAID | 2014 – 2020
\$2,783,692 | 0.6 calendar months |
| <p><u>HIV/AIDS CTU</u>: The goal of this project is to establish a clinical trials site to perform studies in human volunteers in conjunction with various networks established by the NIAID and other agencies.</p> | | | |
| <p>Role: Co-Investigator.</p> | | | |
| 5. | NIH-K12 (Ofotokun/Sterk HD085850)
NICHD | 2015 – 2020
\$466,643 | 1.2 calendar months |
| <p><u>Emory BIRCWH Program</u>: This program will provide career development training and support for early career investigators interested in women's health research and sex/gender science. The ultimate goal is to develop the next generation of leaders in women's health research.</p> | | | |
| <p>Role: PI/Program Director</p> | | | |
| 6. | NIH-R01 (Weitzmann/Ofotokun AR068157)
NIAMS | 2015 – 2020
\$654,899 | 1.2 calendar months |
| <p><u>Accelerated Bone Loss in Aging HIV-infected Individuals</u>: Bone loss is an established complication of aging, HIV/AIDS and ART. This project will improve our understanding of</p> | | | |

the mechanisms involved and how HIV/AIDS and ART affect bone loss in the context of aging. This knowledge is necessary to devise novel therapeutic strategies to preserve/restore bone mass to prevent bone fracture. Role: MPI

7. NIH-R01 (Weitzmann/Ofotokun AR070091) 2016 – 2021 1.2 calendar months
NIAMS \$644,458
IL-4, a key regulator of bone turnover in HIV and ART: This project quantifies the role of IL-4 in the altered B-cell OPG and RANKL and enhanced bone resorption associated with ART-naïve HIV-infected subjects and employ state-of the-art animal models to define the sources and mechanistic functions of IL-4 in the maintenance of physiological bone mass by direct actions on osteoclasts and indirect actions through OPG. Role: MPI
8. NIH-KL2 (Blumberg TR002381) 2017 – 2022 1.2 calendar months
NCATS \$1,305,199
Georgia CTSA Institutional Career Development (KL2): This program is aimed at supporting and fostering the career development of junior investigators interested in clinical and translational research
Role: Co-Investigator/co-Director, KL2 Program
9. NIH-5P30 (del Rio AI050409) 2017 – 2022 0.6 calendar months
NIAID \$815,059
Emory University Center for AIDS Research (CFAR): This award supports the Emory CFAR in all domain of HIV/AIDS research
Role: Co-Investigator/ Co-Director Emory CFAR Clinical Core

b. Pending Awards

1. NIH U01 (Ofotokun/Wingoo/Sheth HL146241) 2019 – 2025 2.4 calendar month
NHLBI \$2,435,000
Atlanta MACS/WIHS Combined Cohort Study Clinical Research Site: The overarching goal of the Atlanta Clinical Research Site (CRS) is to advance the unified scientific agenda of the MACS/WIHS CCS by: a) providing leadership in the development of the unified science protocols; b) serving as a local reading center and support laboratory for studies; and c) leveraging our research infrastructure to implement the CCS protocols by retaining current participants, recruiting new participants from under-represented minority groups.
Role: Principal Investigator
2. NIH-D43 (Ofotokun TW010934) 2019-2024 1.2 calendar months
FIC \$279,999
Emory-Nigeria HIV Research Training Program (EN-RTP): The goal of this project is to enhance the capacity and the quality of researchers focused on HIV health issues relevant to women in Nigeria. To accomplish this, we will leverage existing collaborations between Emory University and three partnering Nigerian institutions to enhance human resource capacity enrichment with long-, medium-, and short-term research training of Nigerian investigators, facilitating their acquisition of the skills needed to pursue research careers focused on women's health and HIV/AIDS. Role: Principal Investigator
3. BWF-PSIA (Ofotokun/Roupheal AI140299) 2019 – 2024 0.6 calendar months
Burroughs Wellcome Fund \$500,000

Emory Physician-Scientist Development Program (EPSDP): The goal of this project is to develop a physician-scientist career development program designed to attract promising clinical track physicians in residency and fellowship training and streamline their smooth transition into the academic research workforce. Role: Contact PI/co-Program Director

- | | | |
|-----------------------|-------------|--------------------|
| 4. NIH U01 (Stephens) | 2019 – 2026 | 1.2 calendar month |
| NIAID | \$19.5M | |

The Infectious Diseases Clinical Research Consortium Leadership Group (IDCRC^{LG} or LG) is a new, collaborative national partnership of leading infectious diseases, human immunology and clinical research experts from eight outstanding academic institutions providing experience, guidance, global connectivity and innovative approaches to address NIH/NIAID clinical research priorities. The emphasis (and strength) of the IDCRC^{LG} is to facilitate, plan and help implement clinical research for respiratory and enteric infections, malaria/tropical diseases, and sexually transmitted infections, and to respond to emerging infectious diseases. Role: Co-Investigator/Chair, Education and Training

b. Other: Mentored Awards

- | | | |
|-----------------------------|-------------|-----------|
| 1. NIH K23 (Sheth AI114401) | 2014 – 2019 | |
| NIAID | Annual Cost | \$174,036 |

Characterization and modulation of mucosal immunity for HIV prevention in women: This study seeks to understand the mucosal immune environment of HIV negative at-risk women and to test the concept that this environment could be pharmacologically modified using a combined antiviral and anti-inflammatory drug in order to inform HIV pre-exposure prophylaxis options for women. This 5-year mentored research-training award additionally supports integrated pharmacology and immunology training to support career development. Role: Primary Mentor

- | | | |
|------------------------------|-------------|-----------|
| 2. NIH K23 (Haddad HD078153) | 2014 – 2019 | |
| NICHD | Annual Cost | \$127,035 |

Impact of progestin contraception on risk of HIV acquisition and transmission: This project will explore the potential mechanisms associated with HIV risk of progestin contraception, and assess the relative impact of 3 progestin-only contraceptives (DMPA, Eng-Implant and LngIUD) on surrogates of HIV susceptibility within the female genital tract. Role: Primary Mentor

- | | | |
|-------------------------------|-------------|----------|
| 3. URC (Titanji) | 2015 – 2020 | |
| University Research Committee | Total Cost | \$30,000 |

Reversing HIV-induced B cell dysfunction with bisphosphonate: This proposal will investigate the contribution of HIV-induced B cell dysfunction to the development of a global proinflammatory state that leads to end-organ damage in aging HIV-infected individuals. We will also interrogate whether this pro-inflammatory state can be ameliorated by treatment with a potent, long acting bisphosphonate, zoledronic acid. Role: Primary Mentor

- | | | |
|-------------------------------|-------------|-----------|
| 4. NIH K01 (Titanji HL131333) | 2015 – 2020 | |
| NIHLBI | Annual Cost | \$105,762 |

Reversing HIV-induced B cell dysfunction with bisphosphonate: This proposal will investigate the contribution of HIV-induced B cell dysfunction to the development of a global proinflammatory state that leads to end-organ damage in aging HIV-infected individuals. We

will also interrogate whether this pro-inflammatory state can be ameliorated by treatment with a potent, long acting bisphosphonate, zoledronic acid. Role: Primary Mentor

5. NIH K23 (Lahiri AI124913) 2016 – 2021
 NIAID Annual Cost \$188,672
Defining Antiretroviral Pharmacology within HIV-1 Reservoirs in males and females: The objectives of this study are to examine antiretroviral pharmacokinetics and viral dynamics within these reservoirs are lacking, particularly in women, in part due to challenges of intensively sampling these hard-to-reach compartments Role: Primary Mentor
6. NIH KL2 (Moran [Scholar] KL2 TR002381) 2018 – 2020
 NCATS Annual Cost \$131,000
 Exploring the role of sex hormones in subclinical cardiovascular disease in women with and without HIV: The objectives of this study are to examine if reduction in circulating estrogen levels and decrease expression of estrogen receptors on cells contribute to HIV associated inflammation and CVD.
 Role: Primary Mentor
- c. Previous Support:
 5. NIH-R01 (Acosta AI058696) 2004 – 2008 1.2 calendar months
 NIAID Annual Cost: \$125,000
Integrating Pharmacokinetics and Antiretroviral Resistance Testing: The primary goals of this project are establish prospective validity and short-term clinical efficacy of a novel methodology that integrates antiretroviral pharmacokinetic information and drug susceptibility data in order to effectively manage highly treatment resistant patients. Role: Co-investigator.
 6. ACTG Minority AIDS Training Program (MATP) (Ofotokun; PI) 2004 – 2006 3.8 calendar months
 NIAID Total Cost: \$92,000
Adult AIDS Clinical Trials Group Minority Training Fellowship Program: This a mentor-oriented HIV/AIDS clinical research training award under the mentorship of Dr. Lennox.
 Role: Trainee.
 7. Office of Global AIDS Coordinator: 2005 – 2006 3.8 calendar months
 President's Emergency Plan For AIDS Relief (PEPFAR) Total Cost: \$183,538
Integrating Digital-Audio Technology and Orality-Based HIV Education to Enhance Awareness: The goal of this project is to scientifically evaluate Voice for Humanity's rural HIV awareness campaign in Africa.
 Role: Principal Investigator for Monitoring and Evaluation.
 8. Emory Medical Care Foundation (Ofotokun; PI) 2005 – 2007
 Total Cost: \$24,675
Pharmacokinetics of an indinavir/ritonavir/amprenavir: The primary goal of this project is to evaluate the pharmacokinetic interaction between these protease inhibitors when concomitantly administered to HIV infected patients. Role: Principal Investigator.
 9. Abbott Laboratories Inc. Ofotokun (PI) 2005 – 2008 0.60 calendar month
 Total Cost: \$98,000

Once Daily lopinavir/ritonavir: A 24-hour Pharmacokinetic Profile to Evaluate Sex Differences

The major goal of this project is to evaluate the sex differences in lopinavir/ritonavir pharmacokinetics.

Role: Principal Investigator.

10. Emory K-12 (David Stephens RR017643) 2006 – 2007 9.0 calendar months
NIH Annual Cost: \$120,000

Impact of Plasma α -1-acid Glycoprotein Variability on Free (unbound) Lopinavir

Pharmacokinetics in HIV-Infected Subjects: The goal of this program is to enable recipient develop an academic career in clinical research under protected mentored environment.

Role: Trainee/Principal Investigator

11. NIH K-23 (Ofotokun A1073119) 2007 – 2012 9.0 calendar months
NIAID Annual Cost: \$128,007

Impact of Plasma α -1-acid Glycoprotein Variability on Lopinavir Levels: The goal of this program is to enable recipient develop an academic career in clinical research under protected mentored environment. Role: Principal Investigator.

12. Merck/Abbott Laboratories Inc. (Ofotokun) 2007 – 2012 0.12 calendar month
Total Cost \$600,000

A Pilot Study to Assess the Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-infected Patients

Role: Principal Investigator.

13. NIH-R01 (Ofotokun AR059363) 2009 – 2015 2.7 calendar months
NIAMS Annual cost \$639,646

Effect of HIV Infection and HAART on Bone Homeostasis: This study will investigate the impact of HIV/HAART on Bone Homeostasis and examine the correlation between B cell and T cell OPG and/or RANKL production in treatment-naïve HIV-infected patients, with indices of bone turnover and structure. Role: Principal Investigator (MPI)

14. Bill & Melinda Gates Foundation (Acosta) 2009 – 2010 1.2 calendar month
Total cost \$244,110

Antiretroviral Quantitation and Modeling in the Female Genital Tract: The goal of this project is to generate predictive PK model to guide the use of antiretrovirals in HIV pre-exposure prophylaxis.

Role: Co-Principal Investigator.

15. NIH-R01 (Ofotokun AG040013) 2011 – 2017 2.4 calendar months
NIA Annual cost \$595,426

Bone Loss and Immune Reconstitution in HIV/AIDS: Osteoporosis is a well known complication of HAART, but the mechanisms remain poorly defined. This proposal will investigate a new hypothesis exploring how immune reconstitution following HAART initiation leads to rapid bone loss. Also, we will test and evaluate the effects of an acute anti-resorptive therapy on preventing skeletal deterioration. Role: Co-Principal Investigator (MPI)

16. NIH-R01 (Holstad NR012923) 2012 – 2016 0.9 calendar months
NINR Annual Cost \$656,958

An Audio Music Self-Management Program to Improve ART Adherence in Rural Georgia. The goal of this project is to evaluate the efficacy of an audio program designed to enhance

knowledge, motivation and self-efficacy about ART adherence among HIV-infected patients in rural communities. Role: Co-Investigator.

17. Bristol-Myers Squibb. (Ofotokun)	2012 – 2016	0.12 calendar month
	Total Cost	\$261,744

Impact of plasma protein binding on CNS free drug penetration for HIV-1 protease inhibitors: The role of the project is to assess the impact of plasma binding protein on CNS compartmentalization of the HIV-1 protease inhibitors.

Role: Principal Investigator.

18. NIH R56 (Quyyumi/Ofotokun HL126558)	2014 – 2016	2.40 calendar month
NHLBI	Annual Cost	\$761,272

Injury and Repair Factors Promoting Atherosclerosis in HIV: The results of the project will increase the understanding of molecular and regenerative pathways and their interactions in HIV-infected subjects, and their influence on risk of presence and progression of vascular disease in this population.

Role: co-Principal Investigator (MPI)

19. NIH R21 (Gandhi AI112362)	2014–2016	0.60 calendar month
NIAID	Annual Cost	\$189,000

Hair measures to assess adherence and explain outcomes in an HIV clinical trial: This proposal seeks to extend the approach of using hair antiretrovirals levels to monitor adherence and exposure to the HIV treatment trial setting, partnering with the ACTG to further test our methodology in a clinical trial which randomized treatment-naïve patients to 3 NNRTI-sparing regimens. Role: Co-investigator

20. NIH KL2 (Lahiri [Scholar] KL2TR000455)	2014 – 2016	
NCATS	Annual Cost	\$131,000

Defining Antiretroviral Pharmacokinetics and Viral Dynamics in HIV-1 Reservoirs: The objectives of this study are to examine the relationship between the pharmacokinetics of dolutegravir and HIV viral decay in blood plasma, peripheral blood mononuclear cells, and rectal tissue using the novel strategy of Pharmacokinetic-Viral Dynamic (PK-VD) modeling.

Role: Primary Mentor

21. BMS (Donahue-Carlson)	2014 – 2015	
Bistol-Myers Squibb Virology Fellowship	Total Cost	\$20,000

Microbiome Composition and Female Genital Tract Compartmental Antiretroviral Drug Exposure in HIV-infected Women: This study will explore the interaction between compartmental antiretroviral drug concentrations and the community of bacterial organisms, the microbiome, in the female genital tract. The findings from this study are aimed to optimize the choice of antiretroviral therapy for the prevention of HIV transmission among women.

22. EMCF (Lahiri)	2015 – 2016	
Emory Medical Care Foundation	Total Cost	\$29,940

Examining Sex Differences in Antiretroviral Pharmacokinetics and Viral Dynamics in HIV-1 Reservoirs: This project will accomplish the following; 1) Validate a novel PK-viral dynamic (VD) model in blood plasma (BP) using dolutegravir (DTG), 2) Develop PK-VD models to describe relationships between DTG exposure and viral load decay in PBMC and rectal tissue

reservoirs, and 3) Use PK-VD modeling to investigate sex differences in DTG exposure-response relationships in BP, PBMC, rectal tissue. Role: Primary Mentor

29. Bibliography:

a. Published and Accepted Research Articles (clinical, basic science, other) in Refereed Journals:

1. **Ofotokun I**, Carlson C, Gitlin S, Elta G, Singleton TP, Markovitz DM Acute cytomegalovirus infection complicated by vascular thrombosis: a case report. *Clin Infect Dis* 2001;32:983-6. PMID: 11247723.
2. Grim SA, Smith KM, Romaneli F, **Ofotokun I**. Treatment of azole-resistant oropharyngeal candidiasis with topical amphotericin B. *Ann Pharmacother* 2002;36:1283-6. PMID: 12196056.
3. Ree R, Jennings JR, **Ofotokun I**. Chronic Mucocutaneous Candidiasis. *JAAPA* 2002;15:6770. PMID: 12012589.
4. Rapp, R.P., Evans, M.E., Martin, C., **Ofotokun, I.**, Empey, K.L., and Armitstead, J.A. Drug Costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital. *Curr Med Res Opinion* 2004;20:469-47.
5. Martin C, **Ofotokun I**, Rapp R, Empey K, Armitstead J, Pomeroy C, Hoven A, Evans M. Results of an antimicrobial control program at a university hospital. *Am J Health Syst Pharm.* 2005;62(7):732-8. PMID: 15790801.
6. **Ofotokun I**, Smithson S, Lu C, Easley KA, Lennox JL. Liver Enzymes Elevation and Immune Reconstitution among Treatment Naïve HIV-Infected Patients Instituting Antiretroviral. *Am J Med Sci* 2007;334(5):334–341. PMID: 18004087
7. **Ofotokun I**, Chuck S, Binongo J, Palau M, Lennox J, Acosta E. Lopinavir/ritonavir pharmacokinetic profile: The impact of sex and other covariates following a change from twice daily to once daily therapy. *Clin Pharmacol.* 2007;47:970-7. PMID: 17615254.
8. **Ofotokun I**, Acosta E, Lennox J, Pan Y, Easley K. Pharmacokinetics of an indinavir-ritonavir/fosamprenavir regimen in patients with human immunodeficiency virus. *Pharmacotherapy.* 2008;28:74-81. PMID: 18154477.
9. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Laloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med.* 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609. PMID:18480202
10. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Laloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med.* 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609. PMID:18480202
11. **Ofotokun I**, Chuck SK, Schmotzer B, O'Neil KL. Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir Soft Gel capsule to tablet in human immunodeficiency virus-infected patients. *AIDS Res Ther.* 2009 Dec 22;6:29. PMID: 20028544.

12. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. *AIDS*. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377. PMID:19417580
13. **Ofotokun I**, Biningo J, Rosenberg E, Kane M, Ifland R, Lennox J, Easley K. Culturally adapted and Audio-technology Assisted HIV/AIDS Awareness and Education program in rural Nigeria: a cohort study: *BMC Int Health Hum Rights*. 2010;10:2. PMID: 20181073
14. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, **Ofotokun I**, Weitzmann MN. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. *Proc Natl Acad Sci U S A*. 2010;107:13848-53. PMID: 20643942.
15. McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA; AIDS Clinical Trials Group A5229 Team. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. *AIDS*. 2010 Oct 23;24(16):2507-15. doi: 10.1097/QAD.0b013e32833ea9bc. PMID:20827170
16. McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA; AIDS Clinical Trials Group A5229 Team. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. *AIDS*. 2010 Oct 23;24(16):2507-15. doi: 10.1097/QAD.0b013e32833ea9bc. PMID:20827170
17. **Ofotokun I**, Lennox JL, Eaton ME, Ritchie JC, Easley KA, Masalovich SE, Long MC, Acosta EP. Immune Activation Mediated Change in Alpha-1-Acid Glycoprotein: Impact on Total and Free Lopinavir Plasma Exposure. *J Clin Pharmacol*. 2011 Nov;51:1539-48. PMID:21209245.
18. Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the Cterminus of HIV-1 reverse transcriptase. *J Acquir Immune Defic Syndr*. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029. PMID: 21350368
19. Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW; AIDS Clinical Trials Group Study A5142 Protocol Team. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the Cterminus of HIV-1 reverse transcriptase. *J Acquir Immune Defic Syndr*. 2011 Apr;56(4):344-8. doi: 10.1097/QAI.0b013e31820cf029. PMID:21350368
20. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaldo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A; Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. Workshop Pharmacogenomics-A Path Towards Personalized HIV Care. *HIV Clin Trials*. 2011 SepOct;12(5):277-85. doi: 10.1310/hct1205-277. PMID:22180526
21. **Ofotokun I**, Sheth AN, Sanford SE, Easley KA, Shenvi N, White K, Eaton ME, Del Rio C, Lennox JL. A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study. *AIDS Res Hum Retroviruses*. 2012 Apr 20. [Epub ahead of print]. PMID: 22364141.

22. Holstad M, Bauman M, **Ofotokun I**, Logwood S. Focus Group Evaluation of the LIVE Network, an Audio Music Program to Promote Antiretroviral Therapy (ART) Adherence Selfmanagement. *Music and Medicine*. 2012;4(2):74-81. PMID:24013689
23. Acosta A, Limoli K, Trinh L, Parkin N, King J, Weidler J, **Ofotokun I**, Petropoulos C. Novel Method to Assess Antiretroviral Target Trough Concentrations Using In Vitro Susceptibility Data. *Antimicrob Agents Chemother*. 2012 Nov;56(11):5938-45. PMID:22964257
24. Ghasemzadeh N, Zhang L, Li Q, Wirtz S, Hritani A, Kumar S, **Ofotokun I**, Guest J, Taylor W, Quyyumi A, Mavromatis K. *J Am Coll Cardiol*. 2013;61(10_S): S0735-1097(13)61143-2.
25. James AM, King KR, **Ofotokun I**, Sheth AN, Acosta EP. Tenofovir and Emtricitabine Uptake into Non-Monocytic Female Genital Tract Cells with and without Hormonal Contraceptives. *Journal of Experimental Pharmacology* 2013;5:1-10.
26. Holstad M, **Ofotokun I**, Higgins M, Logwood S. The LIVE Network: A Music-based Messaging Program to Promote ART Adherence Self-management. *AIDS Behav*. 2013 Nov;17(9):2954-62. PMID:23934269
27. Zaeh S, Kempker R, Stenehjem E, Blumberg HM, **Ofotokun I**, Tenna A. Improving Tuberculosis Screening and Isoniazid Preventative Therapy in an HIV Clinic in Addis Ababa, Ethiopia. *Int J Tuberc Lung Dis*. 2013 Nov;17(11):1396-401. PMID:24125440
28. Wang K, D'Argenio D, Sheth A, Lennox JL, Acosta EP, and **Ofotokun I**. Integrated Model of Lopinavir Pharmacokinetics and HIV-1 Viral Dynamics: The Role of α -1-acid Glycoprotein Binding. *Clin Pharmacokinet*. 2014 Apr;53(4):361-71. PMID:24311282
29. Sheth AN, Evans-Strickfaden T, Haaland R, Martin A, Gatcliffe C, Adesoye A, Omondi MW, Lupo LD, Danavall D, Easley K, Chen CY, Pau CP, Hart C, **Ofotokun I**. HIV-1 Genital Shedding is Suppressed in the Setting of High Genital Antiretroviral Drug Concentrations Throughout the Menstrual Cycle. *J Infect Dis*. 2014 Apr 24. [Epub ahead of print] PMID:24643223
30. Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, **Ofotokun I**. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. *J Clin Pharmacol*. 2014 Apr 1. [Epub ahead of print] PMID:24691856
31. Lennox JL, Landovitz RJ, Ribaldo HJ, **Ofotokun I**, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team. A phase III comparative study of the efficacy and tolerability of three non-nucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve HIV-1-infected volunteers: A randomized controlled study. *Ann Intern Med*. 2014 Oct 7;161(7):461-71. PMID:25285539
32. Titanji K, Vunnava A, Sheth A, Delille C, Lennox J, Easley K, Weitzmann MN, **Ofotokun I**. Altered B cell expression of RANKL and OPG reflects bone resorption in human HIV infection. *PLoS Pathog*. 2014 Nov 13;10(10):e1004497. PMID:25393853
33. **Ofotokun I**, Ribaldo H, Na L, McComsey G, Cohn S, Godfrey C, Sagar M, Aweeka F, Lennox J, Currier J. Darunavir or atazanavir versus raltegravir lipid changes are unlinked to ritonavir exposure: ACTG 5257. *Clin Infect Dis*. 2015 Jun 15;60(12):1842-51. PMID:25767256
34. Lahiri CD, Tao S, Sheth AN, Acosta EP, Marconi VC, Armstrong WS, Schinazi RF, Vunnava

- A, Sanford S, **Ofotokun I**. Impact of Protease Inhibitors on Intracellular Concentration of Tenofovir-Diphosphate Among HIV-1 Infected Patients. *AIDS*. 2015 Apr 13. [Epub ahead of print] PMID:25870991
35. Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaud H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, **Ofotokun I**, Brown T; AIDS Clinical Trials Group A5303 Study Team. Less Bone Loss with Maraviroc- Compared to Tenofovir-Containing Antiretroviral Therapy in the ACTG A5303 Study. *Clin Infect Dis*. 2015 Jun 9. pii: civ455. [Epub ahead of print] PMID: 26060295
36. Vardhanabhuti S, Ribaud H, Raphael Landovitz R, **Ofotokun I**, Lennox J, Currier J, Olson L, Haas D. *UGT1A1* Genotype Predicts Bilirubin-related Discontinuation of Atazanavir/Ritonavir. *Open Forum Infect Dis*. 2015 Jul 1;2(3): PMID:26180834
37. Delille CA, Dugan KB, Burk RD, Palefsky JM, Massad LS, Reimers L, Minkoff H, Xie X, D'Souza G, Xue X, Colie C, Anastos K, Wingood G, Strickler HD, **Ofotokun I**. Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women. *J Acquir Immune Defic Syndr*. 2015 Jul 11. PMID:26181819
38. **Ofotokun I**, Titanji K, Vikulina T, Vunnava A, Roser-Page S, Yamaguchi M, Zayzafoon M, Williams IR, and Weitzmann MN. T-cell Recovery During HIV-1 Antiretroviral Therapy Disrupts the Immuno-Skeletal Interface Driving Bone Resorption and Skeletal Decline. *Nat Commun*. 2015 Sep 22;6:8282. PMID: 26392000
39. Sheth AN, **Ofotokun I**, Buchacz K, Armon C, Chmiel JS, Baker R, Brooks JT, Palella F. Antiretroviral regimen durability in treatment-naïve and treatment-experienced patients by year of treatment initiation, United States, 1998-2008. *J Acquir Immune Defic Syndr*. 2015 Aug 22. [Epub ahead of print]. PMID: 26334737
40. Delille-Lahiri C, Sheth A, Acosta, E, **Ofotokun, I**. Cerebrospinal Fluid Concentrations of Tenofovir and Emtricitabine in the setting of HIV-1 protease inhibitor-based regimen. *J Clin Pharmacol*. 2015 Aug 6. doi: 10.1002/jcph.612. [Epub ahead of print]. PMID: 26247878
41. Haddad LB, Machen LK, Cordes S, Huylebroeck B, Delaney A, **Ofotokun I**, Nguyen ML, Jamieson DJ. Future Desire for Children Among Women Living with HIV in Atlanta, Georgia. *AIDS Care*. 2015 Dec 24:1-5. [Epub ahead of print]. PMID:26702869
42. **Ofotokun I**, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, Rogers K, Sheth A, Lahiri CD, Lennox JL, and Weitzmann MN. Antiretroviral therapy induces rapid increases in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. *AIDS*. 2016;30(3):405-14. PMID:26760232
43. Landovitz RJ, Tran TT, Cohn SE, **Ofotokun I**, Godfrey C, Kuritzkes DR, Lennox JL, Currier JS, Ribaud HJ. HIV Transmission Risk Behavior in a Cohort of HIV-infected Treatment-Naïve Men and Women in the United States. *AIDS Behav*. 2016, 16. [Epub ahead of print] PMID:26979419
44. Swaims AY, Haaland RE, Evans-Strickfaden T, Haddad LB, Sheth AN, Lupo LD, Cordes S, Aguirre AJ, Lupoli KA, Chen CY, **Ofotokun I**, Kohlmeier JE, Hart CE. Recirculating HIV target Progesterone Levels Associate with a Novel Population of CCR5(+)CD38(+) CD4 T Cells Resident in the Genital Mucosa with Lymphoid Trafficking Potential. *JOURNAL OF IMMUNOLOGY*, 197(1), 368-376. PMID:27233960

45. **Ofotokun I**, Titanji K, Lahiri CD, Vunnava A, Foster A, Sanford S, Sheth AN, Lennox JL, Knezevic A, Ward L, Easley K, Powers P, Weitzmann MN. A Single Dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-Induced Bone Loss in Treatment-naïve HIV-infected Patients: A Phase IIb Trial. *Clin Infect Dis*. 2016, 18. pii: ciw331. [Epub ahead of print] PMID:27193748
46. Byambaa E, Erdembileg A, Zhang W, Li CS, Kaplan R, Lazar J, Merenstein D, Karim R, Aouizerat B, Cohen M, Butler K, Pahwa S, **Ofotokun I**, Adimora AA, Golub E, Berglund L. Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study. *Arterioscler Thromb Vasc Biol*. 2017. pii: ATVBAHA.117.309137. doi: 10.1161/ATVBAHA.117.309137. [Epub ahead of print] PMID:28336560
47. Shendre A, Wiener HW, Irvin MR, Aouizerat BE, Overton ET, Lazar J, Liu C, Hodis HN, Limdi NA, Weber KM, Gange SJ, Zhi D, Floris-Moore MA, **Ofotokun I**, Qi Q, Hanna DB, Kaplan RC, Shrestha S. (2017). Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS). *PLOS ONE*, 12(12), 23 pages. PMID: 29206233
48. Bhagwat P, **Ofotokun I**, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. *Antivir Ther*. 2017. doi: 10.3851/IMP3148. [Epub ahead of print] PMID:28248190
49. Hanna DB, Lin J, Post WS, Hodis HN, Xue X, Anastos K, Cohen MH, Gange SJ, Haberlen SA, Heath SL, Lazar JM, Liu C, Mack WJ, **Ofotokun I**, Palella FJ, Tien PC, Witt MD, Landay AL, Kingsley LA, Tracy RP, Kaplan RC. Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men. *J Infect Dis*. 2017. doi: 10.1093/infdis/jix082. [Epub ahead of print] No abstract available. PMID:28199691
50. Enkhmaa B, Anuurad E, Zhang W, Li CS, Kaplan R, Lazar J, Merenstein D, Karim R, Aouizerat B, Cohen M, Butler K, Pahwa S, **Ofotokun I**, Adimora AA, Golub E, Berglund L. (2017). Lipoprotein(a) and HIV Allele-Specific Apolipoprotein(a) Levels Predict Carotid IntimalMedia Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study. *ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY*, 37(5), 997-+. PMID: 283360560
51. Haddad LB, Wall KM, Mehta CC, Golub ET, Rahangdale L, Kempf MC, Karim R, Wright R, Minkoff H, Cohen M, Kassaye S, Cohan D, **Ofotokun I**, Cohn SE. Trends of and factors associated with live-birth and abortion rates among HIV-positive and HIV-negative women. *Am J Obstet Gynecol*. 2017;216(1):71.e1-71.e16. doi: 10.1016/j.ajog.2016.09.079. Epub 2016 Sep 15. PMID:27640942
52. Sarkar M, Dodge JL, Greenblatt RM, Kuniholm MH, DeHovitz J, Plankey M, Kovacs A, French AL, Seaberg EC, **Ofotokun I**, Fischl M, Overton E, Kelly E, Bacchetti P, Peters MG; Women's Interagency HIV Study. (2017). Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. *CLINICAL INFECTIOUS DISEASES*, 65(10). PMID: 29020239

53. Iyer SS, Sabula MJ, Mehta CC, Haddad LB, Brown NL, Amara RR, **Ofotokun I**, Sheth AN. Characteristics of HIV target CD4 T cells collected using different sampling methods from the genital tract of HIV seronegative women. *PLoS One*. 2017 Jun 1;12(6):e0178193. doi: 10.1371/journal.pone.0178193. eCollection 2017. PMID:28570576
54. Turan B, Rogers AJ, Rice WS, Atkins GC, Cohen MH, Wilson TE, Adimora AA, Merenstein D, Adedimeji A, Wentz EL, **Ofotokun I**, Metsch L, Tien PC, Johnson MO, Turan JM, Weiser SD. (2017). Association between Perceived Discrimination in Healthcare Settings and HIV Medication Adherence: Mediating Psychosocial Mechanisms. *AIDS AND BEHAVIOR*, 21(12), 3431-3439. PMID: 29081045
55. Carlson, R. D., Sheth, A. N., Read, T. D., Frisch, M. B., Mehta, C. C., Martin, A., . . . **Ofotokun, I.** (2017). The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy. *JOURNAL OF INFECTIOUS DISEASES*, 216(8), 990-999. PMID: 29029138
56. Weitzmann, M. N., Vikulina, T., Roser-Page, S., Yamaguchi, M., & **Ofotokun, I.** (2017). Homeostatic Expansion of CD4(+) T Cells Promotes Cortical and Trabecular Bone Loss, Whereas CD8(+) T Cells Induce Trabecular Bone Loss Only. *JOURNAL OF INFECTIOUS DISEASES*, 216(9), 1070-1079. PMID:28968828
57. Lesko CR, Todd JV, Cole SR, Edmonds A, Pence BW, Edwards JK, Mack WJ, Bacchetti P, Rubtsova A, Gange SJ, Adimora AA; WIHS. Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. *Ann Epidemiol*. 2017 Dec;27(12):783-789.e2. doi: 10.1016/j.annepidem.2017.08.021. Epub 2017 Sep 5. PMID:28939001
58. Rubin LH, Maki PM, Springer G, Benning L, Anastos K, Gustafson D, Villacres MC, Jiang X, Adimora AA, Waldrop-Valverde D, Vance DE, Bolivar H, Alden C, Martin EM, Valcour VG; Women's Interagency HIV Study. Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression. *Neurology*. 2017 Oct 10;89(15):1594-1603. doi: 10.1212/WNL.0000000000004491. Epub 2017 Sep 13. PMID: 28904086
59. Titanji K, Vunnava A, Foster A, Sheth AN, Lennox JL, Knezevic A, Shenvi N, Easley KA, **Ofotokun I**, Weitzmann MN. (2018). T-cell receptor activator of nuclear factor- κ B ligand/osteoprotegerin imbalance is associated with HIV-induced bone loss in patients with higher CD4+ T-cell counts. *AIDS*: PMID:29424771
60. Moran, C. A., Sheth, A. N., Mehta, C. C., Hanna, D. B., Gustafson, D. R., Plankey, M. W., . . . **Ofotokun, I.** (2018). The association of C-reactive protein with subclinical cardiovascular disease in HIV-infected and HIV-uninfected women. *AIDS*: PMID:29438198
61. Adimora AA, Ramirez C, Benning L, Greenblatt RM, Kempf MC, Tien PC, Kassaye SG, Anastos K, Cohen M, Minkoff H, Wingood G, **Ofotokun I**, Fischl MA, Gange S. Cohort Profile: The Women's Interagency HIV Study (WIHS). *Int J Epidemiol*. 2018 Apr 1;47(2):393-394i. doi: 10.1093/ije/dyy021. PMID:29688497
62. Bekhbat M, Mehta CC, Kelly SD, Vester A, **Ofotokun I**, Felger J, . . . Neigh GN. (2018). HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling. *Psychoneuroendocrinology*, 96, 118-125. doi:10.1016/j.psyneuen.2018.06.013. PMID:29936334

63. Palar K, Frongillo EA, Escobar J, Sheira LA, Wilson TE, Adedimeji AA, Merenstein D, Cohen MH, Wentz EL, Adimora AA, **Ofotokun I**, Metsch L, Tien PC, Turan JM, Weiser SD. (2018). Food Insecurity, Internalized Stigma, and Depressive Symptoms Among Women Living with HIV in the United States. *AIDS Behav.* doi:10.1007/s10461-018-2164-8. PMID:29948333
64. Colasanti J, Galaviz KI, Christina Mehta C, Palar K, Schneider MF, Tien P, Adimora AA, Alcaide M, Cohen MH, Gustafson D, Karim R, Merenstein D, Sharma A, Wingood G, Marconi VC, **Ofotokun I**, Ali MK. Room for Improvement: The HIV-Diabetes Care Continuum Over 15 Years in the Women's Interagency HIV Study. *Open Forum Infect Dis.* 2018 May 22;5(6):ofy121. doi: 10.1093/ofid/ofy121. eCollection 2018 Jun 1. PMID:29942823
65. Lahiri CD, Brown NL, Ryan KJ, Acosta EP, Sheth AN, Mehta CC, Ingersoll MS, **Ofotokun, I**. HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravirbased therapy. *AIDS.* 2018 Jul 12. doi: 10.1097/QAD.0000000000001945. [Epub ahead of print] PMID:30005011
66. Enkhmaa B, Anuurad E, Zhang W, Li CS, Kaplan R, Lazar J, Merenstein D, Karim R, Aouizerat B, Cohen M, Butler K, Pahwa S, **Ofotokun I**, Adimora AA, Golub E, Berglund L. Effect of antiretroviral therapy on allele-associated Lp(a) level in women with HIV in the Women's Interagency HIV Study. *J Lipid Res.* 2018 Jul 16. pii: jlr.P084517. doi: 10.1194/jlr.P084517. [Epub ahead of print] PMID:30012717
67. Whittle HJ, Sheira LA, Frongillo EA, Palar K, Cohen J, Merenstein D, Wilson TE, Adedimeji A, Cohen MH, Adimora AA, **Ofotokun I**, Metsch L, Turan JM, Wentz EL, Tien PC, Weiser SD. Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for HIV in the United States. *Addiction.* 2018 Aug 14. doi: 10.1111/add.14418. [Epub ahead of print] PMID: 30109752
68. Tote KM, Raziano VT, Wall KM, Cordes S, **Ofotokun I**, Haddad LB. Contraceptive method use among HIV-positive women in a US urban outpatient clinic: an exploratory cross-sectional study. *Contraception.* 2018 Aug 1. pii: S0010-7824(18)30393-7. doi: 10.1016/j.contraception.2018.07.140. [Epub ahead of print] PMID:30075117
69. Bhagwat P, **Ofotokun I**, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. *Open Forum Infect Dis.* 2018 Nov 16;5(11):ofy201. doi: 10.1093/ofid/ofy201. eCollection 2018 Nov. PMID:30465010
70. Comeau DL, Alvarez JA, Bhatti P, Quarshi A, Escoffrey C, **Ofotokun I**, Eisen H, Ziegler TR, Blumberg HM. Building Diverse Careers in Clinical and Translational Research: Evaluation of a Certificate Program in Translational Research. In press, *Journal of Clinical and Translational Science*, July 2018.
71. Galaviz KI, Schneider MF, Tien P, Mehta CC, **Ofotokun I**, Colasanti J, Marconi V, Palar K, Wingood G, Adimora AA, Alcaide M, Cohen MH, Gustafson D, Karim R, Konkole-Parker D, Merenstein D, Sharma A, and Ali MK. Predicting diabetes risk among HIV-positive and HIVnegative women: an assessment of the ADA and FINRISC diabetes risk scores. In Press, *AIDS.* 2018 Nov 28;32(18):2767-2775. doi: 10.1097/QAD.0000000000002017. PMID:30289812
72. Leddy AM, Roque A, Sheira LA, Frongillo EA, Landay AL, Adedimeji AA, Wilson TE, Merenstein D, Wentz E, Adimora AA, **Ofotokun I**, Metsch L, Cohen MH, Tien PC, Turan J,

Turan B, Weiser SD. Food insecurity is associated with inflammation among women living with HIV. In press, *Journal of Infectious Diseases*. 2019 Jan 9;219(3):429-436. doi: 10.1093/infdis/jiy511.PMID:30165648

73. Gandhi M, **Ofotokun I**, Bacchetti P, Jin C, Ribaud HJ, Haas DW, Sheth AN, Horng H, Phung N, Kuncze K, Okochi H, Landovitz RJ, Lennox J, Currier JS; and the AIDS Clinical Trials Group (ACTG) 5257 study team. Antiretroviral concentrations in hair strongly predict virologic outcomes in an HIV treatment trial (ACTG 5257). In press, *Clinical Infectious Diseases*, August 2018.
74. Patel AS, Goparaju L, Sales JM, Mehta CC, Blackstock OJ, Seidman D, **Ofotokun I**, Kempf MC, Fischl MA, Golub ET, Adimora AA, French AL, DeHovitz J, Wingood G, Kassaye S, Sheth AN. PrEP Eligibility among At-Risk Women in the Southern US: Associated Factors, Awareness and Acceptability. *J Acquir Immune Defic Syndr*. 2019 Jan 3. doi: 10.1097/QAI.0000000000001950. [Epub ahead of print] PMID:30649036
75. Tuthill EL, Sheira LA, Palar K, Frongillo EA, Wilson TE, Adedimeji A, Merenstein D, Cohen MH, Wentz EL, Adimora AA, **Ofotokun I**, Metsch L, Kushel M, Turan JM, Konkle-Parker D, Tien PC, Weiser SD. Persistent Food Insecurity Is Associated with Adverse Mental Health among Women Living with or at Risk of HIV in the United States. *J Nutr*. 2019 Feb 8. doi: 10.1093/jn/nxy203. [Epub ahead of print] PMID:30753638
76. Mueller KAL, Hanna DB, Ehinger E, Xue X, Baas L, Gawaz MP, Geisler T, Anastos K, Cohen MH, Gange SJ, Heath SL, Lazar JM, Liu C, Mack WJ, **Ofotokun I**, Tien PC, Hodis HN, Landay AL, Kaplan RC, Ley K. Loss of CXCR4 on non-classical monocytes in participants of the Women's Interagency HIV Study (WIHS) with subclinical atherosclerosis. *Cardiovasc Res*. 2018 Dec 5. doi: 10.1093/cvr/cvy292. [Epub ahead of print] PMID:30520941

b. Manuscripts Submitted:

1. Moran CA, Southmayd G, Sheth AN, Quyyumi AA, **Ofotokun I**, Liberman HA, Jaber W, Devireddy CM. Clinical and procedural characteristics of persons living with HIV presenting with acute coronary syndrome. *Catheterization and Cardiovascular Interventions*, in revision, October 9, 2018
2. Inflammation genes are associated with obesity in African Americans and Hispanics: a candidate gene study of the Metabolic Syndrome in the Women's Interagency HIV Study. Natanzon Y, Aouizerat B, Sharm A, Morris N, Adeyemi O, Gustafson D, Liu C, Pearce CL, Irvin M, Dykxhoorn D, Pierce CB, **Ofotokun I**, Tien P, Zhu X. Under review by *J Acquir Immune Defic Syndr*.
3. Gursahaney PY, Cordes S, **Ofotokun I**, Wall KM, Denise J, Jamieson DJ, Haddad LB. Factors Associated with Condom Use Among HIV-positive Women Living in Atlanta, Georgia. *BMJ Sexual & Reproductive Health*.
4. Weiser SD, Sheira LA, Palar K, Kushel M, Wilson T, Adedimeji A, Merenstein D, Cohen M, Turan JM, Metsch LR, Adimora AA, **Ofotokun I**, Wentz E, Tien PC, Frongillo EA. Behavioral and Mental Health Mechanisms partly explain the Negative Effects of Food Insecurity on HIV Treatment Outcomes in U.S. Women Living with HIV. *PLoS Medicine*
5. Whittle HJ, Wolfe WR, Sheira LA, Frongillo EA, Kartika Palar K, Merenstein D, Wilson TE, Adedimeji A, Cohen MH, Adimora AA, **Ofotokun I**, Metsch LR, Turan JM, Wentz EL, Tien PC, Weiser SD. Food insecurity is associated with generalized anxiety, stress, and post-traumatic

stress disorder among women in the United States. *Epidemiology and Psychiatric Sciences* **c**.

Published abstracts

1. Swaims A*, Haaland R; Evans-Strickfaden T, Haadad L, Sheth A, Lupo L, Cordes S, Aguirre A, Lupoli K, Chen CY, **Ofotokun I**, Kohlmeier J, Hart C. Recirculating HIV-target T lymphocytes at the mucosal surface of the female genital tract are associated with progesterone increases during the menstrual cycle. Conference: Annual Meeting of the American-Association-of-Immunologists (IMMUNOLOGY) Location: New Orleans, LA Date: MAY 08-12, 2015, Sponsor(s): Amer Assoc Immunologists JOURNAL OF IMMUNOLOGY Volume: 194 Supplement: 1 Meeting Abstract: MUC2P.938 Published: MAY 1 2015
2. Sheth AN*, Swaims-Kohlmeier A, Haaland RE, Lahiri CD, Carlson RD, Aguirre AJ, Evans-Strickfaden T, Brown NL, Lupo LD, Mehta CB, Hart CE, **Ofotokun I**. Oral Maraviroc Reduces CD4 T Cells at the Genital Mucosal Surface of HIV-seronegative Women: Conference on HIV Research for Prevention (HIV R4P) Location: Chicago, IL Date: OCT 17-20, 2016 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume: 32 Supplement: 1 Pages: 305-305 Meeting Abstract: P18.02 Published: OCT 2016
3. Kohlmeier A*, Haddad L, Haaland R, Lupo D, **Ofotokun I**, Hart C, Kohlmeier JE. Distinct migratory phenotypes of luminal CD4 T cell subsets in the female genital tract. Conference: Annual Meeting of the American-Association-of-Immunologists (AAI) Location: Seattle, WA Date: MAY 13-17, 2016 Sponsor(s): Amer Assoc Immunologists JOURNAL OF IMMUNOLOGY Volume: 196 Supplement: 1 Published: MAY 1 2016
4. Topel ML*, Hayek SH, Wadhvani S, Moran C, Staloch DA, Wei CL (Wei, Reiser J, **Ofotokun I**, Quyyumi AA. HIV-positive Individuals With Undetectable Viral Loads Have suPAR Levels Comparable to HIV-negative Individuals. Scientific Sessions of the American-HeartAssociation on Epidemiology and Prevention/Lifestyle and Cardiometabolic Health. Sponsor(s): Amer Heart Assoc CIRCULATION Volume: 135 Supplement: 1 Meeting Abstract: P261 Published: MAR 7 2017

d. Review Articles:

1. Markovitz DM, Gitlin SD, **Ofotokun I**. Reply to: Thrombosis, vasculitis, and cytomegalovirus infection. *Clin Infect Dis* 2002;34:1659-60.
2. **Ofotokun I**, Pomeroy C. Sex differences in adverse reactions to the antiretroviral drugs. *Top HIV Med* 2003;11:55-9. PMID: 16082059.
3. Grim SA, Romanelli F, Jennings PR, **Ofotokun I**. Late-onset drug fever associated with minocycline: case report and review of the literature. *Pharmacotherapy* 2003;23:1659-62. PMID: 14695046
4. **Ofotokun I**, Busch K, Lee Y, Hoven A. Pulmonary mycobacterium avium complex following immune-reconstitution after HAART therapy. *Infect Dis Clin Pract.* 2004;12:1-3.
5. **Ofotokun I**, Chuck SK, Hitti JE. Antiretroviral pharmacokinetics: A review of sex differences. *Journal of Gender Medicine.* 2007;4;106-119. PMID: 17707845.
6. **Ofotokun I**, Weitzmann M. HIV-1 Infection and Antiretroviral Therapies: Risk Factors for Osteoporosis and Bone Fracture. *Curr Opin Endocrinol Diabetes Obes.* 2010 Dec;17:523-9. PMID: 20844427.
7. **Ofotokun, I.**, and M. N. Weitzmann. 2011. HIV and bone metabolism. *Discov Med* **11**:385-93. PMID:21616037.

8. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaud HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A; Workshop Pharmacogenomics-A Path Towards Personalized HIV Care. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. *HIV Clin Trials*. 2011 Sep-Oct;12(5):277-85. doi: 10.1310/hct1205-277. No abstract available. PMID:22180526
9. **Ofotokun I**, McIntosh E, Weitzmann MN. HIV: Inflammation and bone. *Curr HIV/AIDS* 2012 Mar;9(1):16-25. PMID:22179898
10. James AM, **Ofotokun I**, Sheth AN, Acosta EP, King KR. Tenofovir: Once-daily Dosage in the Management of HIV Infection. *Clinical Medicine Insights: Therapeutics* 2012;4 201-216
11. Remick J, Georgiopoulou V, Marti C, **Ofotokun I**, Kalogeropoulos A, Lewis W, Butler J. Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research. *Circulation*. 2014 Apr 29;129(17):1781-9. PMID:24778120.
12. Ali MK, Magee MJ, Jones TK, Tungsiripat M, **Ofotokun I**, Levitt NS, Rimland D, Armstrong WS. Metabolic and bone disorders in people with HIV: What we know from low and middleincome countries. *J Acquir Immune Defic Syndr*. 2014 Sep 1;67 Suppl 1:S27-39. PMID:25117959
13. Larson KB, Wang K, Delille C, **Ofotokun I**, and Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. *Clin Pharmacokinet*. 2014 Oct;53(10):865-72. PMID:25164142
14. Haddad LB, Polis CB, Sheth AN, Brown J, Kourtis AP, King C, Chakraborty R, **Ofotokun I**. Contraceptive Methods and Risk of HIV Acquisition or Female-to-Male Transmission. *Curr HIV/AIDS Rep*. 2014 Oct 9. PMID:25297973
15. Moran C, Weitzmann MN, **Ofotokun I**. Protease inhibitors and HIV associated bone loss: *Curr Opin HIV AIDS*. 2016 May;11(3):333-42. doi: 10.1097/COH.0000000000000260. PMID:26918650
16. Weitzmann MN, **Ofotokun I**. Physiological and pathophysiological bone turnover-role of the immune system. *Nat Rev Endocrinol*. 2016 Sep;12(9):518-32. doi: 10.1038/nrendo.2016.91. Epub 2016 Jun 17. Review. PMID: 27312863
17. Weitzmann MN, **Ofotokun I**, Titanji K, Sharma A, Yin MT. Bone Loss Among Women Living With HIV. *Curr HIV/AIDS Rep*. 2016 Dec;13(6):367-373. Review. PMID:27678124
18. Moran CA, Weitzmann MN, **Ofotokun I**. Bone Loss in HIV Infection. *Curr Treat Options Infect Dis*. 2017 Mar;9(1):52-67. doi: 10.1007/s40506-017-0109-9. Epub 2017 Feb 23. PMID: 28413362

d. Editorials

1. **Ofotokun, I**. Deciphering how HIV-1 weakens and cracks the bone. *Proc Natl Acad Sci U S A*. 2018 Mar 1. pii: 201801555. doi: 10.1073/pnas.1801555115. [Epub ahead of print] No abstract available. PMID:29496959
2. Frew PM, Lutz CS, **Ofotokun I**, Marconi VC, Del Rio C. Geospatial mapping to identify feasible HIV prevention and treatment strategies that target specific settings. *Ann Transl Med*. 2018 Feb;6(3):59. doi: 10.21037/atm.2017.12.20. PMID: 29610750

e. Book Chapters:

1. **Ofotokun I.** The emerging acquired immunodeficiency syndrome (AIDS) catastrophe in Nigeria. The hope factor: Engaging the Church in the HIV/AIDS crisis. Edited by T. Yamamori, D. Dageforde, T. Bruner Published by Authentic Media, 2003.
 2. Haddad L, Tarleton J, Sheth AN, **Ofotokun I.** "Contraception for women living with HIV." *Contraception for the Medically Challenging Patient.* New York, NY: Springer, 2014.
 3. Sheth AN, Delille C, **Ofotokun I.** Sex Differences in Metabolism and Pharmacokinetics. New York, NY: Springer, 2014.
 4. Lahiri DC, Lennox JL, **Ofotokun I.** Protease Inhibitors. New York, NY: Springer, 2016.
- f. Manuals, Videos, Computer Programs, and Other Teaching Aids:**
1. **Ofotokun I,** University of Kentucky Medical Center 2002-2003 Empiric Antimicrobial Therapy Manual.